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CHAPTER 1. GENERAL INTRODUCTION AND PROBLEM 
STATEMENT 
Mycoplasma hyopneumoniae (MH) is the primary agent of swine enzootic 
pneumonia. 134 This bacterial organism was first identified in the late 1950's and has since 
been recognized as a common inhabitant of swine herds throughout the world.68•134 Recent 
studies estimate that 80% of slaughter hogs have lesions resulting from MH infection. 134 
Although clinical disease is generally mild with low mortality, infection may result in high 
morbidity characterized by chronic coughing. The incidence and severity of clinical disease is 
intensely intertwined with the environment, management practices, presence of other 
bacterial or viral pathogens, herd immunity, and other factors . This complex interplay is a 
consequence of the organism's known effects on the protective mucociliary clearance 
mechanism in the respiratory tract as well as interactions with the hosts immune system 
including evasion and/or alteration of the inflammatory and immune responses to 
infection.48•90 
In the past, MH was nearly always observed as a mixed infection with Pasteurella multocida, 
Haemophilus parasuis and/or Actinobacillus pleuropneumoniae. Of major recent importance is 
MH' s key role in a new syndrome labeled porcine respiratory disease complex (PRDC) 
wherein multiple infectious agents, especially viruses, are involved in producing clinically 
significant respiratory disease generally late in the finishing phase. Primary and/or secondary 
bacterial pathogens, such as Actinobacillus pleuropneumoniae, Pasteurella multocida, 
Streptococcus suis and Actinomyces pyogenes as well as viral agents, including SIV and 
PRRSV have been detected in respiratory disease outbreaks in large finishing units. The most 
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commonly identified pathogens at the Iowa State UniversityVeterinary Diagnostic Laboratory 
(ISU-VDL) in recent cases of PRDC have been MH, PRRSV and SIV.71 
The recent resurgence of MH seems to coincide with the implementation of multiple-
site and larger production systems, perhaps relating to the creation of sub-populations of 
nai·ve animals within infected herds that are subsequently susceptible to infection. Strategies 
for controlling respiratory disease due to mycoplasma, SIV and PRRSV have focused on 
vaccination and management changes including age segregated rearing and/or all in-all out 
movement of pigs by room or building. Even with these control strategies, many producers 
have continued to experience severe respiratory problems in their swine herds. 
Objectives 
MH vaccination appears to induce both cell-mediated and humoral immune 
responses. However, the mechanisms by which these responses develop and how vaccine-
induced immune responses differ from responses to infection have not been fully 
elucidated.92' 109 Our initial objective for the studies reported here was to characterize the 
specific immunoglobulins produced in response to vaccination and/or experimental challenge 
with MH. By sampling and assessing local secretory antibody production and regional lymph 
node responses along with humoral effects via peripheral blood sampling, we hoped to gain a 
better understanding of the pathogenesis of lesion development and the pig's immunological 
responses so that more effective MH vaccines or other control methods could be established. 
Commonly, swine are vaccinated by injection with single dose, modified-live virus 
PRRS vaccines, which must infect the animal's macrophages for an immune response to 
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develop, and killed, adjuvanted mycoplasma bacterins, that generally require two doses. 
Manufacturers recommend giving the first dose of mycoplasma vaccine at 1-3 weeks of age 
followed in two weeks by a second booster injection. In the field, the first MH vaccination is 
commonly administered at or 1-4 weeks after weaning. Since many swine producers 
administer PRRSV vaccine at weaning, prior to the first dose of mycoplasma bacterin, we 
were concerned about the immunological consequences of administering PRRSV vaccines, 
which could potentially disrupt the antigen presenting function of macrophages and thus 
negatively impact the MH vaccination. A recent study showed that concurrent MH and 
PRRSV infections produce a more severe and prolonged pneumonia than could be explained 
by an additive effect alone.163 This presumably results from mycoplasmal interactions with 
virus, immune cells and/or inflammatory cytokines, although the mechanisms are currently 
unknown.163 Thus, as a secondary objective, we evaluated the immunological responses to 
mycoplasma and/or PRRSV vaccination by measuring serum antibody formation, stimulation 
of IFN-y production, and clinical parameters relating to the efficacy of MH vaccination and 
the consequences of MH experimental challenge. 
Thesis Organization 
Contained in this thesis is a general introduction, review of literature, two chapters 
representing separate unpublished research projects investigating our objectives, and a 
general summary. References cited in any of the following chapters are listed following the 
appendices. Tables and figures are numbered independently in each paper. 
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CHAPTER 2. LITERATURE REVIEW 
Etiology 
Mycoplasma hyopneumoniae is a member of the Mollicutes class of bacteria. It is a 
small (200-500 nm) single-celled prokaryotic Gram positive cocco-bacillus. Because of it' s 
small size, MH has high metabolic requirements. Growth in culture is very slow. It does not 
possess a cell wall, instead, the glycocalyx consists of an external carbohydrate layer, an 
intermediate layer predominated by protein and an inner cell membrane.191 Mycoplasmas are 
polymorphic and sensitive to environmental conditions such as osmotic pressure and 
detergents. Members of this class colonize mucosa! surfaces, in particular respiratory, 
urogenital and intestinal tracts, and serosal surfaces such as joints.136 Mycoplasmal disease 
rarely kills the host and conversely, hosts seldom eliminate the organisms rapidly. 
Pathogenic species of mycoplasmas colonize epithelial tissues by binding the 
mycoplasma cell membrane to host cell receptors. 174 Attachment organelles have a role with 
some mycoplasmas whereas others, like MH, have a capsule-like material prominent in 
virulent strains which is speculated to aid in colonization.158 Research has indicated that the 
cell surface of MH is weakly hydrophobic. Trypsin reduces this hydrophobicity, suggesting 
that proteins and/or protein-associated molecules on the cell surface are responsible for 
adherence. 191 The close association results in biochemical changes as mycoplasmas obtain 
metabolic substrates such as lipid precursors and preformed purines and pyrimadines from 
the host.136 Mycoplasmas are unable to synthesis sterols or fatty acids for growth and must 
rely on external sources. 105 Consequently, there is decreased macromolecular synthesis, 
carbohydrate utilization and oxygen uptake in infected ciliated epithelial cells.41 Cell damage 
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occurs due to the release of toxic products, RNA and DNA exo- or endonucleases, 
superoxide and phospholipase.136 Virulence of M. pneumoniae of humans is, in part, due to a 
peroxide hemolysin that diffuses to the host cell membrane and causes injury.42 It is known 
that MH membranes can induce microscopic lesions in pigs 107 and that they can produce in 
vitro cytopathic effects, although other pathogenic factors have not been associated with the 
organism.65 Diagnostic serological tests are based on antibodies to the highly antigenic 
immunologically important components of the glycocalyx and cell membrane. 130 These 
antibodies will inhibit growth and metabolism, produce deformed cells and can, in the 
presence of complement, cause cell lysis. 130 
Mycoplasmas in general are known to greatly affect the immune systems of host 
species via activation of T and B lymphocytes, and secretion of cytokines. Fossum60 found 
detectable levels of serum IL-6 in approximately 30% of apparently healthy conventional pigs 
from herds with a history of APP and/or MH infections. Levels of TNF, IL-1, IL-6 and PGE2 
in bronchoalveolar lavage fluid (BALF) are increased5•6 following experimental MH infection 
while the chemiluminescence (CL) response in neutrophils (PMN) incubated with BALF,7 
phytohemagglutinin-induced transformation of swine lymphocytes90 and phagocytosis by 
porcine alveolar macrophages (PAM)26 were all suppressed. In a study of the pathogenesis of 
APP infection of the respiratory tract, IL-1 and IL-6 were greatly elevated in BALF within 24 
hours of infection. IL-1 was hypothesized to increase the severity of disease however IL-6 
was implied to have a protective role. 117 IL-4 suppressed cytokine production in alveolar 
macrophages after the acute inflammatory response and may have promoted an antigen-
specific humoral immune response. 117 
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The reduction in severity of mycoplasmal pneumonia in immunocompromised 
animals implies that mycoplasmal lesions result, to some extent, from the host's own immune 
response. 157 Immune serum from M. pulmonis-infected mice given to SCID mice 7 days after 
they were infected with M. pulmonis did not increase the severity of disease in the SCID 
mice. However, lymphocytes from uninfected mice injected into SCID mice 1 week before 
infection with M. pulmonis resulted in severe lung disease when compared to infected SCID 
mice not reconstituted with lymphocytes.42 Infected mice have been shown to have higher 
levels of TNF-a and IL-6 production resulting in more severe acute alveolar disease.42 In one 
study antibody did not clear an established M. pulmonis infection and higher levels of 
antibody were associated with more severe disease.42 Researchers concluded that induction 
of cytokine production and lymphocyte activation could either minimize disease or result in 
increased severity.42 
Some mycoplasmas, or at least M. arthritidis, can mediate some activities by 
production of superantigens which are potent immunostimulatory proteins that activate T 
and/or B cells.42 Superantigens may invoke massive cytokine release, may stimulate normally 
quiescent lymphocytes, and may cross-link MHC class II and TCR which can trigger 
autoimmune reactions.42 Nonspecific mitogenic reactions have been reported between 
mycoplasmas and lymphocytes. 107 There is also evidence that some mycoplasmas, such as M. 
pulmonis, can vary their antigenic makeup during the course of an infection thus allowing the 
organism to evade the hosts immune system. 46 
7 
Infection by Mycoplasma hyopneumoniae 
Although lesions due to MH can be induced in pigs of varying ages, most of the 
clinical effects of MH infection are seen in the grow/finish pig which is thought to be the 
major source of infection within a herd. Piffer and Ross 124 studied the effect of age and 
determined that there does not seem to be any difference in susceptibility to MH of contact-
exposed pigs between 3 and 12 weeks of age. They were not able to discern the minimum 
amount of time required for contact transmission to occur. Strasser152 however, indicated 
that pigs inoculated with MH at 2 weeks of age presented with more severe and persistent 
coughing than those infected at 8 weeks of age. 
A natural outbreak of disease in a seropositive herd was investigated by Wallgren.173 
Protection was apparently transferred passively as piglets less than 2 weeks of age were not 
affected while pigs 4 to 7 weeks old developed clinical signs of infection. Antibodies were 
not detected in any of these pigs. Serum was collected from pigs 2 to 11 weeks of age at day 
40 following the development of clinical signs in the herd and from pigs 1 day to 17 weeks of 
age at day 162. Some pigs were then followed by weekly blood sampling until the age of 12 
weeks. An indirect ELISA was used to evaluate antibody levels. After waning of passive 
immunity, pigs had to reach 9 weeks of age or older before they developed seropositive titers 
due to exposure to MH. Peripheral blood mononuclear cells (PBMC) from pigs 1 to 9 weeks 
of age at 290 days after the outbreak were tested in vitro for their capacity to produce 
antibodies (total lg) to a whole cell antigenic preparation of MH. PBMC from 1- to 3-week-
old pigs produced significantly less antibodies than did 5- to 9-week old pigs. The authors 
concluded that the pigs were unable to produce active immunity to MH if younger than 8 
8 
weeks of age and that serum samples from pigs less than 10 weeks of age have little 
diagnostic value unless sow titers are also known. 
Enzootic pneumonia is considered a chronic disease that exhibits a high morbidity 
and low mortality in infected herds. The primary clinical indicator of infection is the 
presence of a dry, nonproductive cough. The cough slowly progresses through the 
susceptible population, continuing for weeks to months, although some pigs may have no 
overt signs of infection. Pigs may appear unthrifty, lacking "bloom" and growth performance 
may be adversely affected even though appetites remain normal . Secondary infections with 
other bacteria and/or viruses may produce severe lung damage, resulting in labored breathing, 
"thumping", fever and death.102 In chronically infected herds, however, pigs that are exposed 
to MH may not show any clinical signs if the herd is managed adequately.39 
There is some controversy over shedding patterns and transmission of the organism 
from sows to their offspring. Clark 36·39 concluded from investigations of herds with enzootic 
pneumonia that sows were a major source of MH. At the same time sows would be expected 
to provide passive immune protection via colostrum in a chronically infected herd. Perhaps 
pigs that are segregated after leaving the farrowing unit never develop clinical signs because 
their colostral immunity is sufficient to prevent transmission of sufficient number of 
organisms for inducing lesions and producing clinical signs.38 Piglets born to higher parity 
sows may have less chance of exposure due to the lower infectiveness of the sows, her 
immune status, the colostral antibody content that can be passed to the pigs and the probable 
extended length of time since the sows were last exposed to MH. In enzootically infected 
herds, it may be advantageous to maintain a higher average parity as older sows would be less 
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likely to transmit MH while gilts and low parity sows probably excrete more microorganisms. 
Recently, however, Clark found sows in the 4th through 61h parities that had 2-fold higher 
antibody titers than sows in the 3rct parity. There was concern that these herds may have an 
unstable iminune status and these older sows could perhaps be shedding the organism to their 
progeny.37 Pig susceptibility will depend on colostral intake and resulting passive antibody 
level as well as age at weaning. 
Seroconversion usually occurs at later stages in the grower/finisher phase, coinciding 
with direct nose-to-nose contact between infected shedding pigs and susceptible pigs, waning 
passive antibody levels, and large numbers of pigs housed in a single air space. Yagihashi 183 
found the highest rate of seroconversion occurred when conventional pigs were 4 months of 
age. Sheldrake141 monitored a continuous-flow commercial farm consisting of four 500-sow 
units that had a recurrent pneumonia problem. Slaughter checks revealed that 62% of pigs 
had pneumonic lesions with an average of 4.5% lung involvement. In this study serum 
samples were obtained from a cohort of pigs at monthly intervals from weaning to slaughter. 
They found the proportion of pigs seroconverting among the age periods< 86 days, 86-115 
days and 115-144 days were 0%, -36% and -96% respectively. 141 There was no correlation 
between antibody titer and level of protection against disease or between antibody titer and 
degree of lung lesions at slaughter. Research has indicated that measurement of humoral 
immunity arising from vaccination does not necessarily predict the level of protection from 
challenge. 165 
Burgi23 evaluated the possibility of transmission from dam to fetus during pregnancy 
since pigs are sometimes obtained by hysterotomy or hysterectomy in an attempt to establish 
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negative herds. As has been previously seen, intravenous inoculation of MH resulted in the 
successful isolation of the organism from various joints, cerebrospinal fluid and/or blood. 101 
In Burgi's study, gilts were intraveneously- or intranasally-inoculated at 5, 8or11 weeks of 
pregnancy with necropsy at 105-109 days of gestation.23 Intranasal inoculation did not result 
in bacteremia and MH was never isolated from any urogenital site or fetus. 23 There may be a 
rare risk of bacteremic blood contamination during surgery such that avoiding the use of sows 
from herds suffering from recent MH infections would be advisable. One source mentioned 
the isolation of MH from one of 101 samples of boar semen, suggesting the possibility that 
artificial insemination could transmit the organism.140 No other studies support this 
conclusion. 
Air-borne transmission may contribute to spread, although to a relatively minor 
degree.114 In the UK, Goodwin67 implied that MH survives quite well in rainwater at lower 
temperatures and suggested that the crucial separation distance for maximum survival was 
about 3.2 km. Some producers whose herds broke with enzootic pneumonia associated the 
occurrence of disease with colder misty conditions, particularly in the fall and winter. 
Pig performance may be adversely affected by MH because of retarded growth. 
Economic losses are associated with reduced rate of gain and feed efficiency.31•112 Studies in 
the past have estimated the decrease in average daily gain to range from 0 to as much as 44% 
of normal. 10 Inconsistent findings may represent inconsistent effects. A recent study 
undertaken in New Zealand included 333 pigs and determined that each 1 % of lung grossly 
affected by enzootic pneumonia resulted in a reduction in average daily gain of 2.2 grams 
while increasing days to slaughter by 0.61 days.31 Effects are not linear and are more 
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pronounced in pigs with severe lesions while pigs with low levels of pneumonia exhibit 
minimal growth depression. 
In one study, feed efficiency was reduced by 14-20% and rate of gain by 16-30% in 
naturally infected swine and the reduced performance increased production costs by $2.80 
(Australian) per pig. 126 In another study, body weight gain of pigs infected at 5-6 weeks of 
age was shown to be decreased by 9.5%, 7.3% and 14.7% compared to controls at 4, 5 and 6 
weeks post-infection, respectively. 80 Expectedly, secondary infections may have an even 
larger impact on performance. Correlating disease and performance would be more accurate 
and cost-effective if the time of infection and, therefore, duration of disease were known 
within an individual herd. These factors are difficult to assess in field situations, while 
experimentally, conditions may vary considerably from normal farm husbandry methods. 
Pigs that have recovered from infection with MH appear to be resistant to infection 
with secondary invaders. In a study done by Amass,2 3 week old pigs from a commercial 
herd were assigned to one of 4 groups with Group 1 moved to isolation immediately while 
Groups 2, 3 and 4 were maintained in the farm's nursery until 11 weeks of age. Group 1 pigs 
were immediately intratracheally challenged with MH, Group 2 pigs were vaccinated against 
MH at 3 and 8 weeks of age and challenged with MH at 12 weeks of age, Group 3 pigs were 
challenged with MH at 12 weeks of age and Group 4 pigs had no treatment. To mimic 
conditions producing enzootic pneumonia, all pigs were subsequently challenged with 
Pasteurella multocida intratracheally at 16 weeks of age and necropsied two weeks later. P. 
multocida is not considered a primary respiratory pathogen of pigs. Pigs in Group 1 began 
coughing 10 days post-infection (PI) with MH and continued for another 46 days. By 13 
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weeks PI they were considered recovered, and, after inoculation with P. multocida, developed 
only mild clinical signs. Group 2 pigs developed transient clinical signs after MI-I challenge 
which were not worsened by exposure to P. multocida (PM). Group 3 pigs had considerable 
exacerbation of cough upon inoculation with P. multocida and this lasted until the end of the 
study. Group 4 pigs developed only transient clinical signs. It was concluded that MI-I 
infection can make the pigs more susceptible to colonization and infection by PM and that by 
comparison of Groups 1 and 3, it took more than four weeks but less than 13 weeks for pigs 
to resolve the MI-I infection. 
In the case of passive immunity, it has been hypothesized that the maternally derived 
serum antibodies may interfere with an active immune response to vaccination and some 
recent investigations support this claim. A study by Thacker et al. (1998) found that vaccine-
induced serum antibody levels in pigs with passive immunity were considerably less than 
levels in pigs without maternal antibody. 159 Most manufacturers of MI-I vaccines recommend 
an initial immunization at one to three weeks of age with a booster dose given two weeks 
later. No vaccine manufacturers have reported the efficacy of vaccination in pigs containing 
maternal antibody at the time of immunization. Some recommendations have been made by 
Clark concerning piglet age at vaccination when piglets are born to immunized sows in an 
SEW system. In this instance, vaccination should be delayed until most of the pigs are 
seronegative by testing or until pigs are about 6 weeks old.37 Passive immunization using 
antiserum has also been thought to be protective but is controversial. In vitro it has been 
shown that damage to tracheal cilia can be averted by incubation with convalescent serum 
from MI-I infected pigs.48 
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Determining for what period of time the organism is present in a pig is difficult. A 
Chinese study indicated that once infected with MH, sows remained infected as long as 661 
days; the organism was isolated from lungs with minimal lesions and homogenated 
suspensions of the lung produced pneumonia when inoculated into pigs.76 Baekbo9 stated 
that infected pigs shed MH until they are at least 10 months old. As part of an eradication 
program in Denmark, all pigs younger than 10 months of age are removed from the farm and 
no farrowings are allowed for a two week period of time during which all remaining animals 
are medicated with an antibiotic such as tiamulin. 8 During the 2 week downtime, all facilities 
and pens are cleaned and disinfected. As a modification of this technique, some have left out 
the disruption in farrowing and instead injected the piglets in the farrowing crates on days 1, 
7 and 14 with tiamulin at a dose of 10 mg/kg.8 Other studies suggest that once lung lesions 
are no longer present, MH cannot be isolated.184 
Infection by direct contact results in slow spread. Although all pigs on a farm may 
seroconvert, pigs raised under proper management and good environmental conditions often 
manifest minimal pneumonic lesions. Conversely, mixing pigs from different sources or 
rearing pigs under poor conditions will result in a higher level of infection along with a 
higher incidence and severity of pneumonic lesions. Oftentimes, pigs of differing age groups 
are continuously mixed, thereby accentuating the transmission of the organism. 
Consequently, the swine industry has moved away from these typical "continuous-flow" 
finishers but infection has still been a problem. 
Management practices may aid in the reduction of pneumonia caused by MH and 
other associated pathogens in a herd. Because of the industry's concern with antibiotic 
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residues in meat and also due to the high cost and variable effectiveness of antibiotic 
treatment, management methods must be thoroughly explored to attempt to control 
respiratory disease. Primary among these strategies in endemically infected herds is limiting 
exposure of young nai've (and thus susceptible) pigs to older grow/finish animals which are 
probably infected and shedding the organism. Such methods include segregated early 
weaning and age-segregated rearing. Facilities should be adapted to all-in/all-out production, 
with limitations of 200-300 animals per room for maximal benefit. Even with the use of all 
in/all out production, there may be pigs that enter a facility already exposed to and infected 
with MH. Such pigs may subsequently shed the organism and expose adjacent pigs as shown 
by progressive seroconversion during the grow/finish period. 101 
Reducing the age spread amongst a group of weaned pigs to not more than two weeks 
and limiting the number of source herds that fill a room or building can also be helpful. 
Weaning age should be four weeks or less (preferably three weeks) to reduce bacterial spread 
from the sow to her offspring.36 Pigs should be allowed adequate facility space as crowding 
is known to greatly increase the severity of respiratory disease. Periodic cleaning and 
disinfecting will reduce overall disease levels. Evaluating ventilation rates and airflow in a 
building may allow for improvement in air quality and thereby decrease environmental 
insults on the lung. Even with the use of these techniques finishing buildings may still have 
occasional outbreaks of clinical disease. 
The use of immunomodulators to influence infectious respiratory disease has recently 
been addressed. Polyunsaturated fatty acids (PUFA), especially (n-3)-derived eicosanoids 
wherein the parent compound is a-linolenic acid [LNA, 18:3(n-3)], taken orally, have shown 
15 
benefits in the cardiovascular system, 139 for chronic rheumatoid arthritis,66 cancer44 and 
kidney disorders49 in man. Fish oil diets containing PUFA decreased TNFa, IL-1~ and IL-2 
production in human peripheral blood monocytes but in mice these diets enhanced TNF and 
IL-1 production.167 
Depending on the study, inflammatory cytokines have been shown to positively or 
negatively impact respiratory disease pathogenesis in different species; thus their role is 
controversial. TNF is secreted by macrophages and T cells in response to endotoxin and viral 
or bacterial infections and leads to increased adhesion of neutrophils to vascular endothelial 
cells as well as increased superoxide production and cellular degranulation.93 TNF can 
induce secretion of IL-1 and GM-CSF which may then act in concert with TNF to stimulate 
release of mediators of endotoxemia and inflammation.93 Levels of 11-1 and TNF in BALF of 
acutely infected (with Pseudomonas aeruginosa) nonimmune rats increased consistently until 
the time of death.22 In immune and subsequently challenged rats TNF enhanced phagocytic 
activity of neutrophils and improved bacterial clearance from the lung.22 IL-2 stimulates 
clonal expansion of T and B cells after introduction of antigen thus most of the time it will 
act as an immunopotentiator and boost effectiveness of vaccines. 142 The two most effective 
types of immunosuppressive drugs used today, cyclosporine and the glucocorticoids, work by 
inhibiting the production of IL-2. 142 IL-1 ~ in pigs is released early and in the highest quantity 
from PAM and to a lesser extent from monocytes, bone marrow and spleen macrophages 
during infectious insult.78 The amount of LPS necessary to trigger IL-1 induction is much 
less in monocytes than PAM but the half life is twice as long in PAM. 78 
In pigs fed PUF A in the form of linseed oil or menhaden oil for four weeks and then 
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intratracheally inoculated with MH and necropsied at three weeks post-infection, gross lung 
lesions were less in treated pigs compared to controls. 167 Lesions increased as the mean ratio 
of (n-3):(n-6) PUFA in alveolar macrophage lipids decreased. The (n-6) PUFA, derived from 
linoleic acid include arachidonic acid and give rise to prostanoids and leukotrienes. The (n-3) 
PUFA may alter the role of TNF because of the increased levels of eicosanoid formation 
from LN A, these being less pro inflammatory. 167 
Recently a study evaluating the effect of dietary n-6-to-n-3 fatty acid ratio on 
complete blood cell counts and T cell subpopulations in beagle dogs was reported. Dogs 
were fed one of three diets varying in amounts of n-6 and n-3 FA. Results indicate that n-3 
FA reduce immune reactivity. Researchers found decreased production of PGE2 and plasma 
concentration of a-tocopherol and increased lipid peroxidation. In response to initial and 
booster vaccinations with keyhole limpet hemocyanin suspension occurring after 8 weeks of 
dietary adjustment to an n-6-to-n-3 fatty acid ratio of 1.4: 1, there were significant increases in 
total numbers of lymphocytes, reductions in the number of CD4+ T cells and decreased 
CD4+ to CD8+ T cell ratios when compared to controls.74 Expression of IL-2R was 
decreased in stimulated lymphocytes. 
Pathogenesis of mycoplasmal infection 
Virulence is defined in Webster's New World Dictionary as the relative infectiveness 
of a microorganism causing disease. Components of virulence may include 1) attachment 
mechanisms, 2) toxin production, 3) induction of detrimental host immune responses, and 4) 
capability of the organism to circumvent or block the host ' s immunological attack. 
17 
Mycoplasma hyopneumoniae naturally adheres to and colonizes ciliated epithelial 
cells of the trachea, bronchi and large bronchioles of the porcine respiratory tract. The 
intimate surface association between organism and cilia is host-specific, as it has been 
shown that MH does not attach to ciliated cells in the respiratory tract of rabbits, guinea pigs 
or lambs.192 The exact mechanism of attachment of the organism to the cilia is unknown, 
although it has been postulated that there are specific MH surface proteins called adhesins 
involved which bind to receptors on the surface of the epithelial target cells. 189•192 It is 
postulated that cilia have specific receptors for mycoplasmal adherence. 126 The receptor 
counterparts on the cilia of porcine respiratory epithelium are thought to be sulfated 
glycoconjugates. 189 The animal cell surface is covered by various forms of carbohydrates 
which are utilized by viruses, bacteria and bacterial toxins as attachment sites.87 
Fibrillar structures present on the surface of MH may also have some function in 
attachment.155 Tajima156 previously observed, using ruthenium red (RR) which complexes 
with osmium tetroxide to stain polyanionic substances, that the capsule seemed to consist of 
radially-oriented fibrillar elements and that this capsular material filled spaces separating 
individual organisms from each other and from the respiratory epithelial surface. They 
compared in vitro- to in vivo-passaged strains of MH and demonstrated that the in vitro-
passaged strains grew poorly in pig lung and were not able to produce gross pneumonic 
lesions. These strains had a much thinner capsule, compared to virulent strains with a 
capsule of up to 40 nm thickness, and no fibrils were seen although there was an amorphous 
fuzzy layer outside the cell membrane. By extracting and purifying the extracellular capsular 
fraction and using a microtiter plate adherence assay, Y oung186 demonstrated that the 
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capsular polysaccharide inhibits MH binding to swine cilia. It is well known that bacterial 
capsular materials can act as anti-phagocytic virulence factors, protect underlying antigens 
from exposure to antibodies and can prevent activation of complement.174 
The adherence mechanisms of other mycoplasmas have been studied and these 
provide valuable information for investigation of the virulence factors of MH. With M. 
pneumoniae and M. gallisepticum, specialized tip-like structures have been deemed necessary 
for adherence. Differences in avidity have been noted in different strains of M. gallisepticum. 
Attachment appears necessary for pathogenicity as it has been shown that avirulent 
mycoplasmas do not adhere to tracheal ring cultures.97 
A strongly immunogenic protein, designated Pl, is one of several that have been 
identified in the binding domain of the attachment end of M. pneumoniae. Antibodies 
formed in sera and respiratory secretions against this protein will inhibit adherence in vitro. 
For immunological typing, two monoclonal antibodies recognize this protein but differ in 
their ability to inhibit adherence to erythrocytes. Proteolytic cleavage experiments have 
demonstrated distinct multiple antigenic determinants and variations in the amino acid 
sequences of this protein, leading to a division of M. pneumoniae into two groups.83 There 
are some avirulent strains that are unable to attach but still possess the Pl protein. 
A large membrane-bound protein of M. bovoculi is highly antigenic and involved in 
adherence. High homologies were found between this protein and human and yeast 
superoxide dismutases (SOD) that generally are intracellular in location. Using 
oligonucleotide probes, SOD was detected in MH and several other mycoplasmas, all of 
which colonize mucosal surfaces. Mycoplasmas associated with systemic infection have not 
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been found to produce these enzymes.131 
Studies of M. hyorhinis infection of mouse lymphocytes indicated that the organism 
could selectively acquire host cell membrane antigens, followed by capping and shedding 
from the surface of the lymphocytes. Ultimately this may lead to blast transformation in 
these cells. Thus some antigens may act as receptors for M. hyorhinis.181 Changes in the host 
cell membrane or alterations in conformation could possibly lead to immunopathologic 
disease. 
Adherence of either whole or solubilized mycoplasmas is temperature and dose 
dependent in vitro. Decreasing temperature results in depressed binding activity and binding 
was found to be minimal at 4° C. 189 Heating to 56° C for 30 minutes reduced binding by 
80% perhaps resulting from conformational changes. 189 Saturated binding was observed with 
greater than 109 CCU of mycoplasmas per well. 189 Viability of l\1lI is not necessary for 
adherence and, in fact, lysed l\1lI organisms have been shown to have a higher level of 
binding ability than whole cells, perhaps due to better exposure of binding sites.189 Optimal 
incubation time for binding was 90 minutes and extended time periods resulted in increased 
background values.189 
Attachment does not seem to be inhibited by diluted convalescent serum perhaps due 
to inefficient coating with antibodies or implying that adhesins are not immunogenic. 
Cytopathogenicity, however, does seem to be suppressed by incubation with hyperimmune 
serum.47 Whole hyperimmune serum containing IgM specific for l\1lI will block adhesion to 
some extent due to its agglutinating activity. This was confirmed by treatment of the serum 
with 2-mercaptoethanol, which causes degradation of the IgM by breaking the disulfide 
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bonds, and in doing so, restores adhesion. 182 Neither MR-specific purified IgG or IgA will 
block adhesion. 192 
Trypsin has been shown to significantly reduce the hydrophobicity of MH and 
pretreatment of mycoplasmas decreased attachment indicating the importance of surface 
proteins or protein-associated molecules. 191 Dextran sulfate is inhibitory indicating portions 
of the receptor(s) may contain sulfur. 189 Dextran appears to bind to mycoplasmas with 
limited affinity as it could be removed by a washing step after pre-incubation. 189 The 
importance of sulfonation of carbohydrate chains in adherence was indicated by the finding 
that certain sulfated glycoconjugates including fucoidan, heparin, chondroitin sulfate A and 
mucin were receptor analogs and were inhibitory if pre-incubated with mycoplasmas. 189 
Sulfate alone was not sufficient however as other sulfated carbohydrates had no effect on 
adherence. 189 Further analysis indicated that there may be some specific sulfate positioning 
requirements for binding to occur. Laminin, a glycoprotein of high molecular weight, 
produced 75% inhibition when pre-incubated with cilia but only 6% when pre-incubated with 
the mycoplasmas. It has been reported that it binds specifically to sulfated glycolipids.189 
Incubation in the absence of salt or at low temperatures decreases adherence 
indicating a role of non-specific hydrophobic interactions in attachment. 191 Such non-
specific low affinity binding may initiate the first phase of adherence until specific high 
affinity adhesin-receptor binding can occur. This hypothesis was proposed by Minion et al. 
in studying interactions between M. pulmonis and RBC surface compounds. 110 Early 
attachment may be followed by molecular rearrangements of the cell surface that exposes 
binding sites. 
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The single ciliated cell adherence assay (SCCAA) by Zhang189 can be used to evaluate 
the association between host cell and organism and the in vivo adherence of MH. Tracheal 
ciliated epithelial cells brushed off the epithelial surface of the trachea are resuspended. Pre-
incubating whole mycoplasmas or cilia with different dilutions of serum, lung lavage fluids, 
or solutions prior to mixing or under differing conditions after mixture. By doing so, it was 
possible to determine whether there was interference with cilial receptors or with 
mycoplasmal adhesins. Some question the subjective results of this test since it is scored by 
fluorescence. Others utilize the microtiter plate adherence assay (MP AA) which measures 
optical density. The latter test uses plates coated with purified cilia at 1 µg of protein per 
well. The degree of binding is affected by the concentration of cilia and the number of 
mycoplasmas in each well. 189 Tetramethyl urea is known to disrupt hydrophobic interactions 
but did not inhibit adherence in the MP AA although it did partially inhibit adherence in the 
SCCAA.189 It was suggested that in the MP AA, the cilial membranes and receptors were 
directly exposed to MH, thus hydrophobic interactions were not necessary.189 
Sodium metaperiodate when pre-incubated with cilia significantly reduced binding.189 
This compound is known to disturb carbohydrate structure. This information and the fact 
that several carbohydrates inhibited adherence suggest that cell receptors are sulfated 
glycoconjugates.189 
Thus it appears that adherence may be multi-phasic, requiring proteins and 
carbohydrates on the surface of the organism, specific components of the host cell membrane 
and other molecular factors as well as hydrophobic interactions.192 
Using monoclonal antibodies, Zhang190 has recently identified and characterized an 
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adhesin, called P97, which is located on the surface of M. hyopneumoniae, as well as its 
glycolipid receptor on the host cell. Purified preparations of P97 will bind to porcine cilia. 
Researchers noted there were variations in the size of this protein, perhaps associated with 
strain differences or antigenic variation, indicating these may be used by MH to help evade 
the immune system. Monoclonal antibodies against this P97 protein can inhibit but not 
entirely block adherence in vitro to ciliated cells; thus P97 may not represent the only adhesin 
of MH. 190 Heparin sulfate and fucoidan blocked adherence of the protein just as well as they 
blocked whole cell adherence. 
Chen et al28 recently identified adhesin-like glycoproteins called Pl 10 and Pl 14, each 
of which consisted of several subunits.28•29 Antisera competitively bound these proteins. The 
native proteins significantly inhibited adherence of the MH cells to biotin-labeled porcine 
tracheal epithelial cell extracts. The subunits were found to be constitutively expressed in 
different strains of MH and in vitro cultivation had little effect on production.29 
Wilton and associates identified a 28 kDa surface antigen of a non-pathogenic strain 
of MH that reacted with monospecific antiserum raised against a larger protein from a 
pathogenic strain. They generated two areas of repetitive DNA sequence (RRl and RR2) in 
the gene encoding for the 94 kDa protein. The gene for this protein demonstrated > 90% 
homology with genes encoding for 2 adhesins, P97 and Mhpl, from pathogenic strains. 180 
Differences in tandem repeats were detected and it was suggested that the variable number of 
repeats in RRl found in different strains of MH might influence ciliary binding. 
A gradual reduction in adherence occurs during successive passages of MH in Friis 
medium. 189 Tajima and Yagihashi determined that passaging cultures as little as six times 
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leads to a loss of pathogenicity. 155 However, a cytopathic factor was still present in sonified 
.MH membranes produced after multiple passages although solubilized .MH exhibited a 
reduced level of adherence with increasing passages.64 Proteolytic cleavage produces 
multiple antigenic determinants. In vitro passage may result in a thinner outer layer of 
capsular material (glycocalyx) which may have an effect on pathogenicity.155 
Pigs infected with .MH generated antibodies against erythrocyte membrane 
glycoproteins in an experiment conducted by Baumgartner and Nicolet.14 These antibodies 
arose simultaneously with the specific .MH antibodies, the specific antibodies not being 
affected by absorption with erythrocyte antigens. This has previously been described for M. 
pneumoniae infection in man in which glycophorin seems to be involved as an adhesion 
mechanism. They, however, failed to detect cold agglutinins (autoantibodies) in the infected 
pigs. Similarities in antigenicity may provide protection from the host immune system. 
With .MH infection there is increased synthesis of phospholipids and a significant 
increase in the total amount of sialic acid in the supernatant of lung lavage and also in blood 
plasma. Lloyd considered that sialic acid may be a factor controlling cell behavior by 
contributing to cell surface structural properties as well as protecting or blocking specific 
glycoproteins from recognition or adhesion.100 It had been hypothesized by Intraraksa79 that 
the mycoplasma-infected lung secretes glycoprotein-containing sialic acid to prevent 
attachment of the mycoplasmas or to decrease proliferation of the number of pathogenic 
agents. Barile considered that mycoplasmal binding to sialic acid may inhibit function of 
these receptor sites resulting in cellular dysfunction.12 Zhang189, however, found that 
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removal of sialic acid from cilia appeared to promote the adherence of MH perhaps due to 
changes in charge or in the configuration of the actual receptors. 
M. hyopneumoniae adheres in vitro to turkey erythrocytes and cell monolayers. It will 
also attach to human lung fibroblasts, porcine lung fibroblasts and porcine kidney cells and 
specific MH antibodies cannot block this attachment. Studies on a new form of in vitro 
adherence model for MH have been reported recently. Using differentiated tracheal epithelial 
cells cultured on permeable membrane supports coated with human placental collagen, 
Young has demonstrated that the model retained most of the morphologic characteristics of 
intact respiratory epithelium.187 Adherence of MH and M. flocculare with resultant cilia 
damage occurred. 
DeBey and Ross evaluated cytopathology using a neonatal pig tracheal ring 
epithelium system. Viable non-passaged lung homogenate or second-passage broth culture 
MH organisms at 105 CCU were necessary to invoke cytotoxicity recognizable at 6 days post-
infection.48 They were able to prevent damage by separating organisms from ciliated 
epithelium with a 0.1-µm-pore-size membrane. Inclusion of MR-infected swine lung 
homogenate, while proven for induction of mycoplasmal pneumonia experimentally, did not 
enhance cytotoxicity in this model. Convalescent swine serum reduced damage but was not 
able to prevent colonization. Attachment of MH to ciliated epithelium was deemed necessary 
to induce cytopathology in this model. 
The ciliostasis and loss of cilia from the respiratory epithelium results from cytopathic 
changes in the epithelial cells. This is thought to be due to the effects of proteases, nucleases 
and lipases, membrane alterations and competition for essential nutrients. 132 
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A study was done by Strasser in Switzerland evaluating whether :MII and M. 
flocculare (MF) would interact and how this interaction would affect the development of 
pneumonic lesions in pigs. MF is considered nonpathogenic although commonly found in 
the respiratory tract of pigs. There is some genetic similarity between the two organisms and 
they cross-react serologically when using certain diagnostic tests. Three MF proteins of 
molecular weights of 110, 47 and 33 kDa were found to react with antibodies to :MII.152 No 
lesions were seen in pigs inoculated with only MF in this study, although an earlier study 
done by Friis found some histological lesions in the nasal cavity and the large bronchi of the 
lung.62 The lesions consisted of diffuse and nodular infiltrations of lymphocytic and 
histiocytic cells with a few neutrophils within the lamina propria and were seen 3 to 5 weeks 
after aerosol inoculation. 
Inoculated animals developed weak titers against MF by 5 to 7 weeks post-infection 
in Strasser' s study.152 As expected :MII produced a much stronger antibody response than 
MF. Pigs infected at two weeks of age exhibited higher titers than those infected at eight 
weeks of age.152 Most experimental animals were still seronegative at 7 to 8 weeks after 
infection although many had titers by 15 to 17 weeks post-infection. The titers that did 
develop were of low magnitude. 152 Other diagnostic tests were evaluated and researchers 
have discerned that immunofluorescence as a diagnostic aid for MF is of little value. They 
did not find any interference of MF with any of the immunoassays for :MII.3 
Interestingly, in preliminary studies investigating the possibility of live :MII vaccines, 
the organism was given experimentally to pigs by multiple routes.101 It was found that 
intravenous or intrathoracic inoculations can produce clinical lameness.101 Multiple joints 
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were involved and affected joints contained cloudy, blood-stained fluid with fibrin. The fluid 
consisted primarily of polymorphonuclear cells. Synovial membranes were thickened; histo-
logically they were infiltrated with mononuclear cells. The organism was cultured from 
affected joints, as well as from the lung. Intraperitoneal administration also resulted in pos-
itive lung culture. 101 Investigators suggested that inoculated pigs may be infective to others. 
Intraderrnal, subcutaneous and intramuscular inoculations lead to isolation of MH 
from local lymph nodes. Peritoneal and pleural fluids were also culture positive for MH after 
intraderrnal inoculation. In any case there were mild peribronchial infiltrations and 
bronchiolar aggregates of mononuclear cells within the lung although MH was not recovered 
from the lung in animals infected by these routes. 101 
Clinical disease 
The incubation period of enzootic pneumonia caused by 1\1H is quite variable, 
dependent on inoculation dose, herd immunity, other infections and environmental factors. 
In a complicated infection, pigs may exhibit anorexia, lethargy, pyrexia and "thumping". 
Clinical disease is not generally seen in pigs less than six weeks of age under field conditions 
however pigs as young as four days of age have been successfully infected experimentally.154 
In 196 MH aerosol-inoculated pigs, Feenstra et al.58 noted coughing beginning at 6 
days PI although it may take up to 2 weeks for coughing to develop after intratracheal 
challenge. Coughing reached a maximum between 3 and 4 weeks PI and stopped by day 58. 
No other clinical symptoms were observed. In pigs necropsied at days 14 and 28 PI, lesions 
were demonstrated in nearly all right apical, right cardiac and left cardiac lobes, and in 
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between 35-60% of the remaining lobes. At 85 days PI, while lesions were almost 
completely resolved, MH was still present in most of the lungs as demonstrated by culture.58 
Intraraksa80 studied physiological changes in the blood and lungs of pigs 
experimentally inoculated at 5-6 weeks of age by intratracheal administration of MH. 
Coughing was observed at 2 weeks post-infection. Pigs had a marked decrease in growth rate 
during the three periods measured. At the 4th, 5th, and 6th weeks after infection, respiratory 
function was evaluated with representative pigs anesthetized. They found decreased lung 
elasticity that resulted in an increase in the animals' respiratory effort. There were increases 
in expiratory flow rate and tidal and minute volumes, along with a significant decrease in 
oxygen consumption. Changes in arterial blood gas parameters included decreases in blood 
pH, partial pressures of 0 2 and C02, and concentration of HC03_. These alterations 
necessitated hyperventilation by the pig to counteract the respiratory acidosis and maintain 
blood pH. Complete blood counts revealed leukocytosis primarily due to neutrophilia, as 
well as a slight lymphopenia. Macroscopic lesions were seen in the lungs at necropsy but 
percentage of lung with pneumonia was not disclosed. 
Lesions 
Lung lesions are distributed cranio-ventrally, suggesting airborne transmission and the 
settling of particles and exudate due to gravity flow. 58 Reflecting the presumed bronchogenic 
distribution, the right apical and cardiac lobes of the lung may be most commonly affected 
because the first bronchus to branch off the trachea supplies the right apical lobe.58 Grossly, 
lesions appear as purple to red areas of "meaty" but not excessively firm consolidation in the 
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apical, cardiac, intermediate, and/or cranial portions of diaphragmatic lobes. 134 Lungs from 
infected pigs may be edematous with increased weight compared to control lungs.51 Mucus 
accumulates in the airways since clearance is reduced, resulting in a catarrhal pneumonia.102 
Often bronchial and mediastinal lymph nodes are enlarged. 102 Secondary infections by other 
pathogens complicate diagnosis by lesions alone. 
The early histopathologic lesions induced by MH infection consist of accumulations 
of neutrophils in airways and inflammatory cells in the walls of blood vessels followed by 
marked peribronchiolar and perivascular mononuclear cell cuffing, eosinophilic exudate in 
alveoli and bronchopneumonia.51 The lymphoreticular hyperplasia indicates significant 
involvement of the cellular immune response in lesion development. In the early post-
infection period after experimental inoculation with MH, there was hyperplasia with 
thickening of the epithelium and organisms were predominantly found closely associated 
with the tips of cilia.21 Mycoplasmas are not generally found lying free in the lumen.21 
Blanchard noted fine fibrils radiating from one mycoplasma to another or to cilia.21 There 
followed a period of reduction in ciliary activity, ciliostasis, sloughing of the cilia and 
exfoliation of epithelial cells.48 In experimental models, cilia were extensively eroded 
between 7 and 20 days post-infection.48 Histologically there was hypertrophy of mucous 
glands in the bronchi resulting in increased mucus production. 13 Hypersecretion of various 
nonsurfactant cellular and acellular components into the airways is thought to occlude the 
airway which then causes atelectasis and cellular invasion.80 The most extensive damage to 
the lung occurs at about 28 days after infection. Experimentally, by six weeks post-infection, 
the epithelial surface was observed to be lacking cilia and desquamated cells were shed into 
the lumen.21 
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Mycoplasmal immunological assays and diagnostics 
Prior to successful cultivation and serological techniques, mycoplasmal organisms 
could be seen in Giemsa-stained fresh lung touch preparations.51 Current methods commonly 
used for identification of MH infected pigs include clinical signs and lesions at 
necropsy/slaughter, culture, tissue immunofluorescence, serum ELISA, and PCR. 
Examination of lungs at slaughter has become the cornerstone of disease surveillance 
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lesions and actual growth performance, the value of slaughter inspections has been intensely 
scrutinized. In most cases, because of slaughter line speed, only cursory rapid examination of 
individual lungs is possible. Each lung lobe's surface area is assigned a relative proportion of 
the whole and then lung lesions are subjectively assessed as a percentage of the lobe. Such 
subjective methods have been compared to actual lesion dissection and weighing of the 
diseased lung, as compared to the whole lung. In one study45 it was found that the subjective 
method was highly predictive of the actual extent of pneumonic lesions. 
However, identification of MH infection within a herd cannot be based on slaughter 
evaluation alone. Results may be misleading due to lesion resolution over time. Pigs infected 
during the early grow-finish phase may have no gross lesions present at slaughter.4 Lesions 
of pneumonia may wax and wane in a dynamic fashion and at any time there may be lesions 
in various stages of development and resolution. Inoculation of specific-pathogen-free swine 
with MH induced lesions that were healed after 60 days, although fissuring lasted more than 
90 days. 58 In such cases, culture can be attempted since MH may still be present in lung 
tissue. Secondary bacterial infections will prolong resolution of lesions. In a study done by 
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Armstrong,4 it was found that 22% of 65 apparently normal lungs from pigs at slaughter were 
shown to be infected with MH by use of indirect immunofluorescence and/or culture. By 85 
days post-infection, Sorensen143 found that lesions were almost completely resolved and there 
were high serum antibody levels but MH could still be demonstrated by culture in the 
majority of lungs. 
In commercial herds there have been attempts to monitor the occurrence of coughing 
in pigs and correlate it to the presence of lung lesions. Attempts have also been made to 
determine the relationship between weight gain and the occurrence of enzootic pneumonia. 
Sorensen145 determined the average time required for the onset of coughing (13 days), and 
from the onset of coughing until seroconversion (22 days) in 138 experimentally-infected 
pigs. Morris 112 found significant correlation between previous coughing episodes and lung 
scores in commercial pigs, but found that weekly assessment of coughing was not a sensitive 
indicator of lung lesions at slaughter. Sorensen 143 found a mean delay of 9 days from the 
onset of coughing in pigs until seroconversion as measured by a monoclonal blocking 
ELISA. 
High, similarly positive predictive values were obtained when comparing culture, IF, 
PCR and ELISA for diagnosis of enzootic pneumonia. Sorensen 143•144 compared these four 
methods for sensitivity and specificity in two separate studies, experimentally infecting 196 
pigs in one study and 200 pigs in the other. Cultivation of the organism was considered the 
"gold standard". In recent infections, negative predictive values of IF, PCR and ELISA are 
comparable to culture, due probably to the large amounts of mycoplasma cells present. Over 
time the negative predictive values of the assays decreased so that in chronic infections, it is 
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recommended that negative results be confirmed by culture. In recent infections, all assays 
were equally sensitive and the newly developed assays were preferred because they are less 
time consuming than culture. 
Although the indirect fluorescent antibody test is quite specific and effective, Clark 
suggests that about 104 organisms per gram of tissue need to be present to achieve a positive 
test.35 An indirect immunoperoxidase staining technique using formalin-fixed, paraffin-
embedded lung tissue may be more sensitive and able to detect low-level infections 
especially in chronically infected swine.52 
DNA probes have been developed for a rapid and accurate identification of 
mycoplasmal infections. Recently Johansson and colleagues85 have synthesized 
oligonucleotide probes complementary to the 16S ribosomal RNA (rRNA) genes of both MH 
and M. hyorhinis. The probes were tested in direct filter hybridization and although there 
was some weak cross-hybridization between MH and M. flocculare with two of the probes, 
one of them (Mhp6/30) was specific for MH. This probe was used successfully to detect MH 
in lung samples from experimentally infected pigs in the acute stage of respiratory disease. 
Gene probes, though, may be unable to detect low numbers of organisms. 150 
As a follow-up to the above study, Thomson166 developed a PCR-based assay for 
detection of MH using two specific primers selecting for the in vitro amplification of a 
fragment of the 16S rRNA gene. Demonstrating MH is difficult because the organism is 
known to have a high degree of genetic drift. The key is finding well-conserved gene 
sequences as appropriate targets so that MH can be differentiated from M. flocculare and M. 
hyorhinis. Thomson ' s assay failed to detect the presence of MH in 10% of lung samples 
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from infected herds perhaps because the amount of organism present was below the detection 
limit of 500 colony forming units. For improved sensitivity, especially in herds with chronic 
disease, it is recommended that multiple lung tissue samples be collected thereby 
concentrating the DNA extract from a single herd. 
In contrast to the classical PCR, Verdin 170 used a two-step (nested) PCR to detect MH 
directly from tracheobronchiolar lavage fluid as well as blood of pigs from birth to 6 months 
of age. In the early stage of infection when most (98%) of the pigs were seronegative, 42% 
were positive by nested PCR. At 6 months, 85% were seropositive and nested PCR positive, 
another 9% were seronegative but nested PCR positive. In another study Stemke149 was able 
to detect and differentiate as little as one mycoplasmal genome from MH and/or M. 
flocculare in lung tissue samples taken from asymptomatic pigs at slaughter. 
Mattsson104 determined that MH can be detected in nasal swabs from naturally 
infected pigs by PCR using primers complementary to the variable regions of the 16S rRNA 
gene from MH. The threshold for successful amplification corresponded to 5 CFU in this 
study. Nasal swabs were collected from grower pigs in a naturally infected herd at 12 weeks 
after arrival and again 3 weeks later. At the first sampling, 5 of 31 pigs were positive by PCR 
(4 of the 5 were also positive by ELISA) and serum antibodies were present in 24 of 31 pigs. 
At the 15-week sampling, of the 5 pigs originally positive by PCR, only 1 pig was still 
positive by PCR. The one pig that was positive by PCR but negative by ELISA at 12 weeks 
became negative by PCR but positive by ELISA at 15 weeks. One ELISA positive pig 
became PCR positive at 15 weeks. At 15 weeks, 30 of 31 pigs tested ELISA positive. 
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PCR done on nasal swabs by Sorensen 143 revealed the presence of MH in 14-18% of 
samples collected on days 11, 25 and 56 post-infection. On day 81 post-infection all nasal 
swabs were negative for MH. This method may be suitable for herd screening although in 
chronic infections it is advisable that further investigation be done using culture to confirm 
the presence of the organism. However, growth of MH from nasal swabs occurred in only 3 
of 506 samples, and only in samples collected within 25 days post-infection. Chinese 
researchers document recovering MH from nasal swabs from 2 of 22 pigs at 418-421 days 
and from lung tissue at necropsy 641-643 days after apparent clinical recovery from 
experimentally induced infections.76 
MH could be detected in air samples of farms where clinically apparent respiratory 
disease was present using a nested PCR assay in a study done by Stark.148 The sampling 
system detected the organism on 80% of the farms involved. No airborne MH was found on 
infected farms without clinical signs. 
Serology is useful as an indicator of exposure to MH. Until recently, while promising 
for its high sensitivity, the standard ELISA had problems with cross-reactions with other 
mycoplasmas, in particular Mycoplasma flocculare,_ a common nonpathogenic inhabitant of 
the respiratory tract of pigs.61 This cross-reactivity produced unacceptable background titers. 
Using antigen solubilized with the neutral detergent Tween 20 rather than sodium dodecyl 
sulfate (SDS) has enhanced the specificity of the indirect ELISA. Tween 20 selectively 
solubilizes superficial membrane proteins that tend to be most imrnunogenic during the 
course of an infection. 119 The antigen can be further purified by use of a chromatography 
column to remove Tween 20. This may increase the sensitivity by about 8 %.18 Harvesting 
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the organisms for producing the test antigen during log phase of culture is also recommended 
to reduce cross-reactivity in serological tests. 135 
ELISA optical density (OD) values have been shown to be positively correlated with 
lung scores and coughing by Bahnson; 11 however as the time from onset of coughing to 
serum collection increased the average OD decreased. In one study by Sorensen, 143 the time 
of peak prevalence of lung lesions following experimental inoculation approximated the time 
of 50% seroconversion among pigs. Antibody titers can be maintained for up to a year post-
infection, and can be assessed using a number of different methods. Following some pigs out 
as far as 8 months post-infection, Sorensen found no association between serum antibody 
level and the persistence of MH in the lung as determined by culture. 143 
Feld59 developed a monoclonal blocking ELISA utilizing an MH specific epitope on a 
molecule of approximately 74 kDa. Assay specificity was more dependent on the detector 
antibody rather than on the antigen in a blocking ELISA and there were no cross reactions 
with M. flocculare. 
Sorensen 146 compared monoclonal blocking ELISA results from colostrum with those 
from serum in a breeding herd with verified MH infection. There was higher test sensitivity 
for colostrum samples than for serum samples, with highest specificity if colostral samples 
were taken close to the time of farrowing. Almost half of sows with positive colostral 
samples turned negative by 18 hours after farrowing. Because colostral levels drop so 
rapidly, later-born piglets may have lower serum lgG than their littermates. 113 Analyzing 
colostrum samples would seem to be useful in detecting infection within a herd. Information 
on the sow's immune status could reliably predict passive serum antibody concentration in 
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her piglets if there were a perfect dose-response relationship, i.e. if no external factors 
affected the passive transfer of antibodies. However, sow and piglet nursing behaviors, milk 
production, and colostral intake are some of the factors that are going to vary between litters 
and piglets. 
Levonen98 reported that IgG antibody concentrated in sow colostrum could identify 
MB-infected herds prior to any antibody appearing in the serum. Antibodies appeared in the 
colostrum four days to six months before the development of clinical disease. Specificity 
with this ELISA was 99.6% but sensitivity was much lower (66.7%). Zimmermann194 
determined that some serologically negative (using a commercially available ELISA kit) 
sows had colostral antibodies. Since 40% of milk samples were positive versus 20% of 
serum samples, and milk sample collection is much simpler than blood sampling, they 
concluded that milk testing was superior. There were more positive samples in herds with 
clinical infections compared to herds with subclinical infections, as would be expected. 
Another study by Zimmermann195 indicated that titers in colostrum were one to 5 
times higher than titers in blood. As already demonstrated, some sows had antibodies only in 
colostrum and not in blood while the reverse was never true. Titers in colostrum fall off 
rapidly as determined by sampling of 203 sows. In two chronically infected herds, an average 
of approximately 30% of sows were colostral positive on the day of farrowing but by day 2 
this had decreased to approximately 10% of samples. In three recently infected herds, almost 
90% of sows were positive on the day of farrowing and this decreased to about 45% on the 
second day. 
Depending on the laboratory and the extraction method, identification of a 36 kDa151 
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or 43 kDa50 protein, which seems specific to MH and has been cloned and purified, has also 
enabled a high degree of specificity in testing methods used. Anti-P36 antibody recognized 
the P36 protein of all strains of MH tested and showed no cross reactions with any protein of 
several mycoplasma and acholeplasma species occurring not only in swine, but also in other 
animals and in humans. Antibody to purified antigen was detected by ELISA at 2-3 weeks 
after experimental challenge and persisted until 24 weeks post-infection. 151 
Culture is considered the diagnostic "gold standard" for MH, but it may not be 
feasible in all cases. Although very specific, culture may not be very sensitive because it is 
difficult to perform, time-consuming and requires special media. Friis63 prepared a medium 
for growth of MH which included Hanke' s balanced salt solution, Bacto brain heart infusion, 
Bacto PPLO broth, yeast extract, phenol red solution, bacitracin, meticillin, thallium acetate, 
pig serum and water to achieve isotonicity. The pH of this medium is adjusted to 7.4 and 
growth is indicated by a color change from red to yellow. Unless specifically suppressed, 
cultures are often quickly overgrown by Mycoplasma hyorhinis, a common secondary invader 
of the swine respiratory tract, as well as Mycoplasma flocculare, making it difficult to 
identify the slower growing MH. Whittlestone179 suggested several options for overcoming 
M. hyorhinis including using antiserum or specific inhibitors in the media, increasing the 
concentration of serum in the media which favors the growth of MH and making 5-7 
passages at weekly intervals, after which MH but not M. hyorhinis continues to multiply. 
Fluorescent antibody testing can be done on positive cultures for absolute identification. 
Various comparisons have been made of the available diagnostic tests and many times, 
combinations of tests need to be utilized for accurate assessment and for timely application of 
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preventive and treatment methods.11 •125·143 
Mycoplasmal immunization 
Passive immunization with serum containing antibodies to MH may provide some 
protection against the development of pneumonia as demonstrated by Lam and Switzer.95 
However Irigoyen81 came to the opposite conclusion, that it was not protective. In the latter 
study, two groups of four-week-old pigs were given 4.4 or 2.2 ml/kg of MH antiserum while 
another group was given 2.2 ml/kg of serum from seronegative (susceptible) pigs. All 
injections were done intraperitoneally. Pigs subsequently received MH by intratracheal 
challenge six hours following administration of antiserum and were necropsied four weeks 
after challenge. ELISA antibody titers were demonstrable in passively immunized pigs but 
there were no differences in coughing index, gross and microscopic lesions and culture 
results between passively treated and control pigs. Antibody titers in the group of pigs given 
4.4 ml/kg of antiserum were at the highest (an E-Value of 2.1, negative< 1.0) on day 1 but 
declined to negative at 14 days after challenge. If serum antibody is indeed protective it is 
not known what level is necessary to achieve this protection. Other methods of defense 
including cell mediated immunity or localized antibody secretion may be necessary for the 
development of complete protection. 
Initial attempts at Mycoplasma hyopneumoniae vaccination involved administration 
of 2 doses of a mixture of Freund' s incomplete adjuvant with formalin-killed whole 
organisms or with supemate or saline wash of cultures, both of which may also have 
contained whole cells or membranes.137 All of these methods were shown to provide 
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protection against experimental challenge. Vaccines prepared by freeze-thaw saline solution 
extracts produced variable results with some indication that such treatment may have 
enhanced lesion development, perhaps related to a superantigen effect. In a study by 
Kristensen92 pigs vaccinated with inactivated MH organisms in Freund's complete adjuvant 
demonstrated considerable antibody titers and induction of cell mediated immunity as 
evaluated in vitro by incorporation of tritiated thymidine in peripheral blood lymphocytes 
upon exposure to antigen (blastogenesis). However, upon field exposure vaccinated pigs 
developed systemic illness with fevers and severe pneumonia while non-vaccinated animals 
did not. Apparently, with this vaccine preparation prior sensitization of the immune system 
was detrimental and resulted in more severe clinical effects. 
Vaccines usually contain a series of antigenic proteins that vary depending on the 
manufacturer. In some cases the specific proteins and their relative amounts in the vaccine 
can be directly related to severity of lesion development post-challenge.84 During growth in 
vitro, MH may not express the virulence factors that may be required for survival in vivo. 
Therefore a major difficulty with strains of MH adapted for growth in culture is that they may 
have mutated and are not expressing significant quantities of the essential protective antigens. 
Quite possibly, inactivating or preservation processes may destroy important antigens. 
Passive, colostrum-derived immunity appears to interfere with response to 
vaccination. A study by Thacker et al. (1998) measured titers of pigs that were vaccinated 
while they still had passive antibodies and found them to be lower than those of pigs that 
were vaccinated when they had no passive antibodies.159 Weng did not vaccinate pigs but 
followed the antibody progression of ten piglets determined to have high maternal antibody 
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levels. They used an IHA test on serum samples collected weekly. Two pigs became 
negative at 2 weeks, 7 pigs were negative at 6 weeks, and all pigs were negative at 9 weeks. 
176 Durisic took blood samples from piglets born to sows given an intramammary vaccine at 
12-20 days prior to farrowing. Antibodies were found in the colostral whey from both 
inoculated and uninoculated mammary glands. In the pigs serum antibodies were detected 4-
8 hours after farrowing. 54 Serum levels fell during the first week of life and then were 
maintained at lower levels until the third to eighth week of age.54 Morris found that sow MH 
colostral titers were, on average, 54% higher than their serum titers, although they were well 
correlated. 113 Passive antibodies have been shown by these researchers to have a median 
half-life of approximately 15.8 days with median time to the lowest antibody concentrations 
being 44 days. 113 Another study measured initial antibody concentrations in the piglets and 
classified them as low, medium or high, with the antibodies waning at 30, 45, and 63 days, 
respectively. 102 The amount of passive antibody acquired can vary greatly between litters as 
well as between pigs in the same litter. This is most likely due to ingestion of varying levels 
of colostrum, suckling behavior of the piglets, milk production by the sow, and her nursing 
behavior as well as her immune status. 102 
In a survey of conventional swine herds in Japan in which 72% of sows were 
seropositive, Yagihashi found that pigs born to sows in the "high" antibody group became 
seronegative by waning of passive antibodies at 30-90 days of age. 183 Four of 5 litters of 
pigs from these sows subsequently became protected via active immunity in response to MH 
exposure by 140 days of age. Pigs in the "low" antibody group were negative through 90 
days of age and all but one litter were still negative at 140 days. Both groups had high 
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antibody levels at 180 days of age. Based on this data, it appeared that pigs with high passive 
antibody titers develop active immune titers earlier and at higher levels than pigs with low 
passive antibody levels which would suggest that there is a higher prevalence of MH 
shedding among sows.183 This conclusion is inconsistent with the findings of others.38 
Antibodies found in pigs less than 2 months of age could be assumed to be passively acquired 
whereas in pigs 3-4 months of age these antibodies probably result from active infection. 183 
Numerous studies have indicated that in endemically-infected herds, vaccination 
against MH can be cost-effective and beneficial. 165 Strategic integration of management 
technologies including biosecurity, pig movement, design of facilities and usage of 
antibiotics as well as serological testing and vaccination can optimize results.37 Time-tables 
for vaccine usage will differ with the different management systems used on the farms. 
Studies have shown reduced lung lesions, improved average daily gain and feed efficiency 
and fewer days to market in vaccinated herds.37·84·115•165·177 
Weng and Chu175 found that IgM was detected in serum by IHA at one week 
following primary intramuscular MH vaccination, lgG could be found at two weeks while 
lgM was starting to decrease. One week after booster vaccination, lgM and IgG levels 
increased sharply. IgM decreased and lgG increased slightly at two weeks following booster 
vaccination. Tracheobronchial washings had only IgG fractions that were detectable at 6 
weeks after second vaccination. 
Both cellular and humoral aspects of the immune response can be enhanced by 
incorporating dextran sulfate into a vaccine containing nonviable MH organisms. Dextran 
sulfate has been found to be cytotoxic to macrophages and will enhance a delayed 
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hypersensitivity reaction to nonviable M. pulmonis in mice.89 Kishima evaluated 
transformation of lymphocytes from pigs vaccinated four times with MH plus dextran sulfate 
(DS), MH alone, DS alone or saline control (positive and negative). Two weeks after final 
vaccination, pigs were challenged via intratracheal administration of MH. Blood samples 
were obtained weekly to test for responsiveness of lymphocytes. Pigs given MH plus DS 
exhibited transformation of lymphocytes marked by the enhanced incorporation of tridiated 
thymidine [3H thymidine] beginning 1 week after the 2nd vaccination in the first experiment 
and 1 week after the 1st vaccination in the second experiment. 91 Before challenge, 
stimulation was not observed in any of the other groups. Necropsy at five weeks after 
challenge revealed that the severity of pneumonia was markedly less in pigs vaccinated with 
MH plus DS.91 Overall transformation of lymphocytes was markedly greater in the MH plus 
DS group. Antibody titers detected by complement fixation test were higher also. 
It is thought that some vaccine adjuvants may act directly on dendritic cells and 
effectively stimulate their migration to local lymph nodes. Antigen presenting cells can be 
stimulated by adjuvants to secrete cytokines that act on lymphocytes to promote 
predominantly T helper 1 or T helper 2 immune responses. Some adjuvants, such as 
immunostimulating compounds (ISCOMS) and liposomes, may induce cytotoxic T 
lymphocytes (CTL's) through the delivery of antigen directly to the cytosol for presentations 
with major histocompatability (MHC) class I molecules, thus bypassing endosomal delivery. 
The benefits of incorporating adjuvants into vaccine formulations to enhance 
immunogenicity must be weighed against the risk of these agents to induce adverse reactions 
such as inflammation at the injection site which can lead to sterile abscess formation and 
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even systemic reactions. 
Recently, a recombinant 11-kDa protein fused to a j3-galactosidase was examined as 
an experimental vaccine. Pigs vaccinated with this hybrid protein had significantly lower 
mean lung scores than unvaccinated controls after challenge, but there were no significant 
differences in performance of pigs as determined by mean average daily live weight gain 
through 126 days of age.57 
A recent area of investigation has been the induction of protection mediated by a 
common mucosal immune system shared by the gastrointestinal, reproductive and respiratory 
tracts. It is thought that nruve lymphocytes that circulate through the body express homing 
receptors for mucosal and peripheral secondary lymphoid tissue. They are primed by 
interaction with antigen in lymph nodes or other lymphoid tissue. Primed lymphocytes then 
home to tissues related to their site of initial activation where they are able to proliferate if re-
exposed to antigen. 
Although rather unorthodox and of little use commercially, inoculation of sonified 
:MH antigens directly onto the Peyer's patches of the small intestine in conventional or 
caesarian-derived, colostrum-deprived (CDCD) pigs protected 50-70% of them from 
challenge with virulent organism.33 Major concerns with mucosal immunization include 
instability of the immunogen due to pH, bile salts and proteolytic enzymes of the stomach 
and intestinal tract, induction of tolerance to soluble antigens, and inefficiency of antigen 
uptake.33 
Recently there has been successful oral delivery of antigen by entrapping it in 
biodegradable microspheres which can be readily transported from the lumen of the intestinal 
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tract by specialized M cells to the underlying antigen presenting cells. Testing the use of 
rnicroencapsulation, Weng used cellulose acetate phthalate as a coating material for different 
sized rnicrospheres of the freeze-dried MH vaccine. 177 They achieved protection in 4-week-
old pigs using an initial intramuscular vaccination with formalin-killed MH at 109-10 color-
changing units of viable organisms per ml followed in two weeks by an oral vaccination. 
Challenge occurred 14 days after the oral vaccination, and necropsy was conducted 28 days 
after challenge. Challenged but non-vaccinated control pigs exhibited a mean lung score of 
over 21 % compared to vaccinated pigs with scores ranging from 0.5 to 7.4%.177 The particle 
size of the oral vaccine did not significantly affect results. 
The cytokines TNF-a, IL-1 and IFN-y are generally considered important in the 
recruitment and activation of phagocytic cells in the lung. In one study rats were immunized 
with Pseudomonas aeruginosa via the gut-associated lymphoid tissue prior to intratracheal 
inoculation with the same organism. This resulted in early, high but transient levels of TNF-
a in the bronchoalveolar lavage fluid (BALF) while levels of IL-1 remained low. 22 Increased 
recruitment and phagocytic activity of alveolar macrophages and neutrophils contributed to 
pulmonary protection by enhancing bacterial clearance. Acutely infected nonimmune control 
rats generated increasing levels of both TNF-a and IL-1 in BALF and sustained damage to 
tissue relating to high levels of IL-1. The high level of TNF-a in immunized rats apparently 
prevented the production of IL-1. Other cytokines such as IL-4 and IL-10, both of which are 
produced by T cells, can increase the synthesis of IL-1 receptor antagonists and concurrently 
decrease that of IL-1.93 In the infected lung, it is assumed that T cells are activated and 
presumably secreting cytokines.22 Immunized rats also had higher levels of IFN-y in the 
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BALF than did unimmunized controls and exhibited enhanced bacterial clearance after 
infection.22 
Animal model studies of Mycoplasma pneumoniae infection indicate that oral 
vaccination of animals using a heat-killed bacterial suspension did not result in an IgG 
response, whereas parenteral vaccination did.34 After live challenge, parenterally vaccinated 
animals mounted an early accentuated histopathological response in lung tissue which 
included perivascular infiltrates while oral vaccination did not.34 Such response may provide 
for increased clearance of bacteria from the lung although it is admittedly deleterious to the 
host.34 This leads one to wonder whether stimulation of the humoral or cellular or both 
components of the immune system are desirable. 
There has been progress made recently in increasing the levels of antigenic proteins in 
vaccines or incorporating newly identified proteins as detected by immunoblots in order to 
produce a superior vaccine.84 Such vaccines appear to reduce lung lesions even more, in 
direct relation to the amount of mycoplasmal protein in the formulation. 84•150 
Only a few individual proteins of MH have been identified and characterized, thus 
little progress has been made in the development of subunit vaccines. King sequenced and 
cloned a gene encoding a protein called Mhp 1 which appears similar to and may be a variant 
of the p97 protein described by Zhang and thought to be an adhesin.88•19° Fused to a gene 
from Schistosoma japonicum, the recombinant antigen was recognized by sera from pigs 
infected with MH. An experiment utilizing four groups was conducted in which groups were 
nonvaccinated, adjuvant (consisting of Freund's complete and Freund's incomplete 
adjuvants) injected only, given a commercial vaccine or given recombinant GST-.Mhpl 
46 
vaccine with Freund's complete adjuvant. Use of the recombinant vaccine resulted in less 
coughing and fewer coughing days, although not significant, and no difference in 
macroscopic lung lesions.88 
DNA vectored vaccines, in which naked plasmid DNA is inoculated and taken up by 
host cells with the subsequent expression of foreign proteins, is a more recent approach. It is 
thought that the resulting enhanced mucosal immunity as well as the generation of systemic 
antibody production can provide substantial protection. Some researchers are investigating 
the use of MH surface proteins including P97 protein, an adhesin involved in attaching to 
cilia of the respiratory epithelium, in bacterins, vaccinal membrane preparations and also in 
DNA vaccines.88 By reducing adherence, presumably pigs would be better protected against 
colonization and subsequent disease. 
The immune response to mycoplasmal infection 
Presentation of antigen to the immune system is the necessary first step in the general 
mechanisms of the immune response. Although many cell types can be involved, it is the 
type of professional antigen presenting cell (APC) that is thought to determine the response. 
Macrophages, dendritic cells and B (lymphocyte) cells process and present antigen in 
association with major histocompatability complex (MHC) class I or II molecules to the T 
(lymphocyte) cells and provide the boost of accessory cell functions which result in activation 
or suppression of humoral or cellular effector pathways. 
T helper (Th) cells are activated by APCs. Although intermediate patterns exist, in 
the mouse there are mainly two types of Th cells. Thl cells produce the cytokines IFNy and 
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IL2 when activated and promote cell-mediated immunity particularly monocyte/macrophage-
mediated inflammatory responses with production of cytotoxic T cells and IgG2a antibody 
production. 116 Th2 cells facilitate B cell development and augment humoral immunity, e.g. 
IgE and IgA production, via secretion of IlA, IL5, IL-6 and ILlO. The cytokines produced by 
Thl cells have an autostimulatory effect on Thl cells as well as an inhibitory effect on Th2 
cells and vice versa.20 Thus, activation of Thl and Th2 subsets can be mutually exclusive. 
Researchers have concluded that in the normal lung, T cells constitute a higher 
proportion of lymphocytes than they do in the blood or lymph nodes, suggesting that they 
must have an important role in lung function. 120 Although not considered a lymphoid organ, 
the lung of the pig contains vast quantities of lymphocytes which have been 
compartmentalized into the pulmonary intravascular pool, the interstitial lymphocyte pool, 
the bronchus-associated lymphoid tissue (BALT) which is seen as analogous to the gut-
associated lymphoid tissue (GALT) and in particular Peyer's patches, the intraepithelial and 
lamina propria lymphocytes of the bronchi, and finally, the lymphocytes in the 
bronchoalveolar spaces.120 Lymphocytes reach the lung via the blood where a sizeable 
number of them temporarily lodge on the vessel wall. In the pig, lymphocytes recirculate 
from the bronchoalveolar spaces to the pulmonary lymph nodes rather than up the 
mucociliary apparatus. This allows for more intense surveillance and thus initiation and 
maintenance of immune reactions.53 The BALT in pigs and man appears to result from 
antigenic stimulation as it is not present in normal healthy lung tissue.121 
The complexities of :MII and its fastidious growth requirements have made attempts 
to identify and characterize immunogens difficult. Differing growth conditions can result in 
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the expression of different proteins. Phenotypically similar MR strains seem to be very 
heterogeneous thus complicating immunological issues. Immunoblot analysis of the 
serological response of pigs experimentally challenged with MR have yielded differing 
results. In one study, Young and Ross found that swine direct their immune response toward 
proteins of about molecular weights 36, 41 , 50, 64, and 110 kilodaltons.188 They identified 
strain specific immunogens from both pathogenic and nonpathogenic strains. 135 Others have 
identified responses mainly to the 76 K, 70 Kand 46 K antigenic components at 3 weeks 
postinoculation, followed by antibodies to the 96 K and 38 K at 4 weeks and then at 11 
weeks the 53 K components.111 Still others identify antigens of molecular mass 36, 43, 76, 
94, 114 and 200 kDa as being MR-specific.138 These conflicting results may be explained by 
differences in the strain of MR used, the degree of in vitro passaging, laboratory techniques, 
the method and dose of inoculation, consistency of numbering by researchers, individual 
animal differences, etc. Also, minor differences in antigenic size may be related to the use of 
different molecular mass markers.138 
Pigs that were intranasally inoculated twice at a three-hour interval with a 10% 
pneumonic lung suspension harvested from MR-infected pigs had serologically detectable 
MR-specific IgM which disappeared by 4 weeks post-inoculation. There were traces of IgG 
at 2 weeks with a gradual increase until 12 weeks and some persisted until the end of the 
study (54 weeks). There were low levels of IgA at 4 and 6 weeks. IgA was found in 
tracheobronchial secretions at 2 weeks, mainly IgA with some IgG at 6 and 12 weeks, while 
from 20 weeks until the end of the trial, only IgA was detectable.175 
Contact exposed pigs had responses similar to the intranasally inoculated pigs. 
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Serologically, IgM was detected at 4 weeks, only IgG was present at 6 weeks, it peaked at 12 
weeks and persisted until the end of the trial. IgA was detected in tracheobronchial washings 
at 6 weeks and persisted to the end of the study. 
In a study done comparing ELISA, CF and RID assays, antibodies in serum were first 
detected at 3 weeks, 2 weeks and 5 weeks post-infection, respectively. 18 In another study, 
pigs were inoculated intratracheally and sera and airway lavage fluids were collected at 
intervals postinoculation and assayed by ELISA and immunoblotting. Antibody responses 
were slow to develop and were quite variable among the pigs. The earliest responses in 
airway washings were IgA isotype antibodies beginning at 30 days postinoculation, followed 
by IgG antibodies.185 Other studies found IgG levels to rise more rapidly. 171 Normally, deep 
in the lung tissue, IgG becomes the predominate immunoglobulin isotype found in most 
species of animals highlighting the importance of its opsonic activity in enhancing alveolar 
macrophage function. 171 A ratio of at least 4: 1 of IgG:IgA producing B-cells was noted at 4-5 
weeks postinfection in lung and bronchial lymph nodes compared to a pre-exposure IgA:IgG 
ratio of 0.7: 1.171 During infection, IgM increases were moderate. Suter determined that in 
BALF, IgM and IgG elevations were detected early with IgA steadily increasing with time.154 
In sera, IgA antibodies were undetectable or at very low levels, IgG and IgM antibodies were 
detected at 45 days and peaked at 80 days postinoculation. 185 
Indirect hemagglutination assays have revealed serum titers as early as one week after 
small intestine mucosal (Peyer' s patch) inoculation of MH. Lung IHA titers, and especially 
lung IHA titers from pigs inoculated with sonified MH antigens, were always higher than 
serum titers.33 
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Sheldrake55 detected significant serum antibodies using ELISA by 9 days after 
intratracheal inoculation. Such early detection of antibodies was possible, it was 
hypothesized, because of the repeat monitoring of specific animals. Determination of 
infection using a single blood sample as a diagnostic test would not be reliable in their 
estimation until about 40 days post-infection. Titers increased steadily until about 60 days 
post-infection at which time they began to decrease at a slower rate. 
Immunosuppression may play an important role in pathogenesis. Researchers have 
found a suppressive effect of killed MH whole cells on phytohemagglutinin-induced 
transformation (blastogenesis) of peripheral blood lymphocytes as well as enhancement of T 
suppressor cell activity.90 Heating MH at 60° C or higher temperatures for 30 minutes can 
apparently destroy the factor(s) involved and prevent suppression. This would appear to 
indicate that the factor is proteinaceous. There is some suggestion, however, that these 
decreased stimulation indices upon exposure to MH could arise because of depletion of 
medium constituents that are essential for lymphocyte function.90 
Membranes of MH have been found to induce microscopic lesions in pigs.107 
Membranes from the organism have also been shown to cause cytotoxic damage to tissue 
culture monolayers, i.e. human lung fibroblast cell lines. Specific factor(s) isolated from MH 
membranes have been shown to be cytotoxic for porcine and human fibroblasts. Geary and 
Walczak65 isolated a 54 kDa factor that induced a cytopathic effect in MRC-5 human lung 
fibroblast culture. In another study by Geary et al.,64 they identified and isolated two 
cytopathic factors, termed cytopathic factor I (CFI) and cytopathic factor II (CFII), from MH 
membranes. The damage caused by CFII was identical to that caused by viable MH or MH 
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membranes. CFI had more subtle effects. 
Surface structures of the mycoplasmas could aid in modulating or evading the host's 
immune response. 136 Direct competition of MH for metabolic substrates and elaboration of 
exo- or endo-nucleases could damage host cell mechanisms. Messier and Ross 108 found 
evidence of trafficking and compartmentalization shown by increases in responsiveness of 
bronchial lymph node lymphocytes. These lymphocytes were sensitized by respiratory tract 
exposure to MH membrane antigens prepared by osmotic lysis of mycoplasma cells. 
A number of the mycoplasmas have been shown to trigger a nonspecific mitogenic 
response for B and/or T lymphocytes in vitro perhaps due to the production of so-called 
superantigens. Superantigens bind to MHC class II molecules with high affinity but outside 
of the peptide groove and without any conventional processing by the antigen presenting 
cell. 129 They interact with the TCR through a V~ gene segment shared by a large fraction of 
the total T cell pool. 129 M. arthritidis mitogen (MAM) is the best studied. 129 Messier109 
showed that MH infection increased nonspecific mitogenesis in bronchial lymph node and 
blood lymphocytes. 
Porcine alveolar macrophages (PAM) are an integral part of the pulmonary immune 
defense mechanism of the pig. Monocytes/macrophages originate from a common stem cell 
and populate multiple organs/tissues while displaying a variety of immunologic functions. 
Even within one tissue, the cells may be divided into several subpopulations showing 
differing phenotypes and functions. In a study done by Choi 171 PAM obtained via 
bronchoalveolar lavage and subjected to discontinuous Percoll density centrifugation were 
found to consist of five subpopulations varying in their surface marker expression and 
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function. Evaluation of functions included phagocytosis of bacteria, Fe-receptor expression 
via rosette formation, production of superoxide anion and release of TNF-a upon stimulation 
with LPS. Cells with higher densities demonstrated increased functional abilities but 
decreased Fe-receptor expression; these differences were perhaps related to their level of 
maturation/activation within the lung. It was found that each subpopulation exhibited 
different susceptibility to PRRSV infection. Increasing densities yielded increasing levels of 
infectious virus. 
Altered alveolar macrophage function has been noted in the MR-infected lung. 
Alveolar macrophages collected at necropsy from MR-infected pigs showed increased in 
vitro phagocytic capabilities compared to those collected from uninfected littermates. Caruso 
and Ross demonstrated that MR in combination with Actinobacillus pleuropneumoniae 
suppressed phagocytosis by alveolar macrophages. 26 
Kristensen92 detected sensitized lymphocytes in the peripheral blood at 3 to 4 weeks 
post-infection with maximum responses seen at weeks 6 to 9. Blastogenesis done in the 
same study varied from week-to-week but was markedly higher in lymphocytes from 
vaccinated pigs. Some low-level mitogenicity was noted in unvaccinated animals. 
Evidence is accumulating about the roles cytokines play in the direction of the 
immune and inflammatory responses to antigenic stimulation. In the presence of bacterial 
lipopolysaccharides (LPS), macrophages release TNF-a which initiates dendritic cell 
migration to regional lymph nodes and, along with GM-CSF, recruits and activates 
leukocytes. TNF-a also recruits and activates neutrophils. GM-CSF and IL-1 promote 
maturation of the dendritic cells leading to an upregulation of MRC class II and also 
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increasing the efficacy of antigen presenting cells. This localized response at the antigenic 
site is considered the first cytokine cascade. 1 
Studies with M. pneumoniae demonstrated TNF-a release from activated murine 
resident peritoneal macrophage cells. In particular, one study posed the question whether the 
cytokine's release is influenced by phagocytosis or if it simply requires direct contact 
between macrophages and the organism.106 Macrophages were co-cultured with one of the 
following: viable, heat-killed, sonicated, or opsonized M. pneumoniae cells. TNF-a 
concentration in the supernatants were measured after 1, 3, 8, and 24 hours of incubation by 
standard cytotoxicity bioassay. Results obtained were similar for all groups except the heat-
killed organisms, which had undetectable levels of TNF-a indicating the thermo-labile nature 
of the activating factor. 106 Levels of cytokine were not influenced by phagocytosis. 106 
After migration to the lymph node, dendritic cells initiate the second cytokine cascade 
by producing IL-12 which induces development of CD4 T cells. For activation of resting T 
cells, it is thought that the soluble factor(s) produced by antigen presenting cells plus IL-2 is 
required. The combination of TNF-a, IL-1 and IL-2 has been hypothesized to upregulate IL-
2R expression on T cells, IL-2 also functioning to upregulate TNF-a receptor. By such 
actions effector T cells can be recruited at the site of the immune stimulus and a pool of 
memory T cells can be maintained peripherally. 168 Without IL-2, all possible combinations 
of IL-1~, TNF- a and IL-6 did not result in any response, in one study.68 With IL-2, which 
usually implies an antigen specific T cell activation, CD4 T cells respond by proliferating and 
producing IFN-y which is thought to drive the cell-mediated immune response.68 
Mycoplasmas are capable of inducing increased expression of MHC class II antigens 
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in macrophage cell lines and cultures by increasing transcriptional activity of MHC genes.153 
IFN-y enhances NK and macrophage activity and can increase MHC expression, and thus 
contribute to antigen presentation, in a wide variety of cell types.153 Stuart153 investigated the 
mechanism of mycoplasma-induced increases in MHC expression and performed 
experiments testing whether this results from direct action of mycoplasmas on the cells or 
from a cytokine mediator, assuming a uniform mechanism. Of four possible cytokine 
candidates for this action, three, namely IFN-y, IL-4 and GM-CSF, have been tested and 
found not to be involved. Further studies on the role of TNF-a are yet to be reported. 
Experimentally, levels of IL-I , IL-6, TNF-a and PGE2 are seen to be persistently 
elevated in bronchoalveolar fluids of MR-infected pigs post-inoculation.5•6 In one study, 
samples of BALF were obtained at I4 days and 27 days post-infection with necropsy 
occurring on day 32-TNF-a and IL-I were elevated at 27 and 32 days.5 Elevated levels of 
IL-I and TNF-a in bronchoalveolar lavage fluid (BALF) were significantly correlated with 
gross and microscopic lesions of MH.5 These cytokines seem to be contributors to the 
development of pneumonic lesions in infected pigs and are generally known to enhance 
neutrophil responsiveness to stimuli and to activate T lymphocytes.7 
Mycoplasma pneumoniae is apparently cleared from the lung through alveolar 
macrophages and, experimentally, increased levels of TNF-a, IL-I, and IL-6 mRNA 
expression are found within the macrophages. These cytokines mediate neutrophil 
recruitment (TNF-a and IL-I) and induce acute phase proteins (IL-6).42 Lin99 found that 
natural cytotoxic effector cells respond to mycoplasma infection and mediate cell lysis by 
releasing TNF-a which may be part of a protective host response to the mycoplasmas. 
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IL-1 and TNF-a are also known to induce production of IL-6 and PGE-2. Mean IL-6 
levels in BALF were significantly elevated beginning 2 weeks after MH inoculation where 
they appeared to plateau and remain approximately the same at 3 and 4 weeks. PGE-2 
activity was highest at 4 weeks post-infection which is later than that for IL-6, perhaps 
relating to a different production pathway. Levels of IL-6 were shown to be significantly 
increased in pigs with pneumonic lesions. BALF cytokine levels may have continued to 
increase after this point but all pigs were necropsied at 4 weeks, which is considered the time 
of maximal gross lung lesion development, so no further testing was performed. 
In one of these studies by Asai5, BALF primarily consisted of alveolar macrophages at 
14 days PI, whereas samples taken at 27 and 32 days PI were composed of 
polymorphonuclear cells and lymphocytes. Exactly which cells were involved in release of 
the specific cytokines was not determined. 
Another study by Asai7 evaluated the effect of BALF from MR-infected pigs on 
chemiluminescence of peripheral neutrophils stimulated with opsonized zymozan. Their 
findings suggested that the observed suppression was primarily due to prostaglandin E2 
(PGE2) as they found significant correlation between the suppressive effect of BALF and the 
concentration of PGE2 in the BALF. They eliminated direct interaction of MH with the 
neutrophils by centrifugation and filtration through a 0.2 µm pore-sized membrane filter. 
They were also able to suppress porcine neutrophil function with purified human PGE2. 
Other soluble factors may play a role in modulating polymorphonuclear cell function. The 
suppression of cell function could account for the increased severity of secondary pneumonia 
due to Pasteurella multocida or Actinobacillus pleuropneumoniae in MH infected pigs. 
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Clinical pneumonia due to MH or other infectious agents apparently induces 
increased levels of serum alpha-1-acid glycoprotein in pigs. This acute phase protein is one 
of several produced by hepatocytes in response to systemic cytokines (IL-1, IL-6 and TNF-a) 
which are released following inflammation and tissue injury.55 Levels may be correlated with 
growth performance.56 This could be useful as a monitor of general, overall herd health 
status.82 
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CHAPTER 3. ELISPOT, FACS AND ELISA EVALUATION OF 
IMMUNE RESPONSES TO MYCOPLASMA HYOPNEUMONIAE IN 
VACCINATED AND/OR CHALLENGED PIGS 
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Abstract 
Preliminary work suggests that the primary leukocyte cell populations infiltrating and 
forming nodules in the lung of Mycoplasma hyopneumoniae (MH)-infected pigs are Band 
CD4+CD8+ lymphocytes.96 Because of the significant numbers of B lymphocytes, it was 
thought that determination of the specific isotypes of antibodies secreted by these cells may 
provide some insight into the mechanisms of pathogenesis and development of lesions. 
Previously, researchers have found IgG-producing lymphocytes in the lung of MR-inoculated 
pigs, with numbers increasing as the disease progressed, while there were none in control 
pigs. 109 In the study reported here, pigs were subjected to one of four treatments: 
mycoplasma vaccination only, vaccination plus mycoplasma challenge, challenge only or 
nonvaccinated/noninfected controls. Blood was sampled serially and pigs were evaluated 
clinically throughout the trial. At necropsy 28 days after challenge, lung lesions were 
assessed and lung and lymph node samples were taken to assess lymphocyte cell populations 
and detect immunoglobulin secretion. Vaccination plus MH challenge resulted in high serum 
ELISA titers, reduced coughing scores, reduced the percentage of lung exhibiting lesions and 
increased the total number and percentage of B cells in the lung. In comparison to challenge 
alone, vaccination plus challenge produced an increased percentage of CD4+ and 
CD4+/CD8+ T cells in the lung. Vaccination obviously does not completely protect against 
58 
MH challenge as pneumonia was not eliminated. Non vaccinated, challenged pigs exhibited a 
higher percentage of gross lung lesions (mean of 5.93 % ) while non-challenged pigs 
exhibited no evidence of pneumonia. We found a non-specific IgM response to MH cell 
membranes "in all tissues from all groups. The stimulation of both B and T cells in this 
experiment suggest that both cellular and humeral immune systems are involved in response 
to mycoplasmal antigens presented by vaccination and/or challenge. 
Introduction 
In species other than pigs, mycoplasmal pneumonia is characterized by a lymphoid 
infiltrate consisting primarily of T lymphocytes bearing the CD4+ differentiation marker.77 
Cells so designated are classified as T-helper cells. Preliminary work with swine suggests 
that primary populations in the lung of MR-infected pigs are Band CD4+CD8+ (double 
positive) lymphocytes.96 It is known that T cell depletion results in reduced lymphocyte 
infiltration into the lung of MH infected pigs. 157 T cell depletion can be induced in pigs by 
thymectomy and treatment with antithymocyte serum. After such treatment, the extent of 
perivascular and peribronchiolar cuffing by lymphocytes in response to MH infection appears 
less prominent. 157 However with such treatment, MH growth was enhanced, exudation into 
airways more severe and the organism was found to spread systemically.157 These findings 
indicate that cell-mediated immune responses are integral in the development of typical MH 
pneumonia. 157 
Walker171 estimated at least a 5-fold increase in the total number of leukocytes in lung 
tissue 28 days following MH challenge. The proportion of B cells in bronchoalveolar lavage 
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fluid and lung tissue of infected pigs increased by 4-5 times over normal and B cell numbers 
doubled in the draining lymph node. Suter, however, estimated that only about 1 % of the 
total number of lg positive cells present in the lung following MR infection are producing 
antibodies specific for MR. 154 
In Walker's study, pigs were repeatedly inoculated with MR and then allowed to rest 
8-12 weeks before receiving a high dose challenge. At 4 days following the latter challenge, 
B cells were evaluated using antibody-secreting probes. The B cells localized to the lung and 
bronchial lymph nodes, particularly those draining the apical lung lobes, responded to a more 
restricted repertoire of antigens compared to B cells from serum.171 This procedure, referred 
to as antibody secreting cell probes (ASC), may be a useful approach for monitoring localized 
B cell responses and for recognizing specific antigens expressed by pathogens in vivo. 
One study concluded that IgG, present in tracheobronchial washings in vaccinated 
pigs, was not associated with any gross or microscopic pneumonic lesions and thus probably 
arose from the serum. 175 Since IgA was the major antibody detected in tracheobronchial 
washings from infected pigs while at the same time IgG was the primary serum antibody, it 
seems that the local immune response can be initiated independently from the systemic 
immune response. A co-infection model of the porcine respiratory disease complex 
evaluated BALF antibodies and found by day 10 post-challenge there were significant levels 
of MR-specific IgG present in vaccinated pigs.164 There were elevated, although variable, 
levels of IgA and consistent increases in IgG levels in pigs both MR-vaccinated and MR-




Significant numbers of lymphocytes surround and invade blood vessels and airways, 
contributing to the pathologic lesions within the lung of the MB-infected pig. Our goal was 
to compare the specific isotypes of antibodies secreted by the B lymphocytes in the MH-
vaccinated and/or infected pig lung which may then provide some insight into the 
mechanisms of pathogenesis of the disease and vaccine-induced protection against the 
development of lesions. 
Materials and methods 
Twenty-one mycoplasma-free pigs were obtained and randomly assigned to one of 
four groups with stratification by weight and sex. Each group was housed in separate 
isolation rooms. The pigs were subjected to one of the following treatments: MH challenge 
only (Group 1), MH vaccination plus MH challenge (Group 2), MH vaccination only (Group 
3) or control (Group 4, nonvaccinated/noninfected). At three weeks of age (one week after 
arrival) the first dose of a commercial killed MH bacterina was administered to pigs in 
Groups 2 and 3 according to the manufacturer's recommendations, followed by a booster 
vaccination in two weeks. Serum was obtained for MH antibody testing from all pigs at 
allocation, challenge, two weeks post-challenge and necropsy (four weeks post-challenge). 
All serum samples were kept frozen and assayed by ELISA at one time. 
a Respisure™, Pfizer Animal Health, Exton, PA 
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Challenge 
Three weeks after the second vaccination the pigs in Groups 1 and 2 were challenged. 
For the challenge, 10 ml of a 1: 100 dilution of 10% crude lung homogenateb of pneumonic 
lung from a pig inoculated with Mycoplasma hyopneumoniae strain 11 was administered as 
previously described.173 Daily observations were made of all groups after challenge for 
coughing or other clinical signs of disease. 
Necropsy and pathology 
At 21 days post-challenge, 7 of the pigs were anesthetized using intravenous 
barbiturates, euthanized by exsanguination and necropsied. The thorax was opened and the 
lung photographed in situ. Peripheral blood and sterile samples of bronchial lymph nodes 
and lung were collected for lymphocyte isolation. Lung tissue was collected for culture, 
histology and FA. A veterinary pathologist graded lung tissue microscopically on the degree 
of peribronchiolar and perivascular lymphoid hyperplasia, cuffing, and/or nodule formation, 
septal thickening, mononuclear cell accumulation, bronchopneumonia and alveolitis. 
Bronchial lymph node weights were obtained. Lesions of macroscopic mycoplasmal 
pneumonia were sketched using diagrams of the dorsal and ventral surfaces as previously 
described by Neurand et al. 174 The percentage of lung involved was subsequently determined 
using an image analysis system.c At 28 days post-challenge, 8 pigs were euthanized 
following the same techniques. The final 6 pigs were euthanized on day 29. 
b Courtesy of Dr. Richard Ross Laboratory, Veterinary Medical Research Institute, Ames, IA 
c Zeiss, Thornwood, NY 
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Flow cytometry 
Mononuclear cells were isolated from each of the tissue samples by direct differential 
centrifugation over ficoll Histopaqued 1077 as previously described by Thacker. 162 For 
blood, ten ml of heparinized peripheral blood was added to an equal volume of PBS and then 
layered onto 9 ml of warmed ficoll. For lung and lymph nodes the tissues were minced and 
forced through a sterile 150-mesh stainless steel sieve to remove connective tissue fragments, 
rinsed with PBS and diluted with PBS. The cells were then layered onto ficoll. Ficoll/tissue 
samples were centrifuged for 30 minutes at 2500 rpm. The cloudy leukocyte interface layer 
was removed using a glass pasteur pipette, transferred into 2 tubes and each tube was diluted 
to 12 ml with PBS for washing. Tubes were centrifuged at 1500 rpm for 10 minutes and the 
supernatant discarded. Cells were combined into one tube, resuspended in 10 ml PBS and 
centrifuged at 1000 rpm for 10 minutes. Cells were washed once more in the same manner. 
Peripheral blood samples were treated with 1 ml of sterile water followed by 3 ml of sterile 
I 
saline and then 5 ml of PBS to lyse contaminating erythrocytes. After a final wash, the 
supernatant was discarded and the cell concentration was determined with a Coulter 
Countere. Cells were diluted to a final concentration of 2 X 106 cells/ml of RPMr1 with 10% 
FCS, 100 U/ml penicillin G, 100 µg/ml streptomycin and 0.05 mg/ml gentamicin sulfate. 
Flow cytometric analysis was performed as previously described by Thacker.162 
Briefly, a 100 µl aliquot of each sample was added to each of four wells labeled Neg 
d Sigma Chemical Co., St. Louis, MO 
° Coulter Electronics Inc., Hialeah, FL 
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(negative), PE/FITC, Band CD4/CD8 in round bottom 96 well microtiter platel Plates 
were centrifuged increasing to 2100 rpm and then declining over a 3 to 5 minute period and 
buffer was aspirated from each well. Monoclonal antibodies specific for CD4g and CD8g 
were mixed to a concentration of 1:50 in FACs buffer (consisting of 1 % bovine serum 
albumin and 0.1 % sodium azide in PBS) and 50 µl of the mixture was added to each well in 
the CD4/CD8 column. FACs buffer only (100 µl) was added to remaining wells. Plates were 
incubated on ice for 30 minutes, then centrifuged to 2100 rpm as described before. The 
CD4/CD8 wells were washed with FACs buffer, plates centrifuged and buffer aspirated from 
wells a total of 3 times. 
Anti-swine IgG antibodyd conjugated to FITC was mixed with FACs buffer at 1:50 
concentration. A 50 µl aliquot was added to each well in the B column of the plates. Isotype 
IgG2a (CD4) antibody conjugated to PE ct was mixed at 1:200 dilution with FACs buffer. 
Isotype IgG2b (CDS) antibody conjugated to FITC ct was mixed at 1:25 with FACs buffer. A 
50 µl aliquot of each was added to each well in the CD4/CD8 column. Fifty µl each of 
Isotype PEct mixed at 1:500 with FACs buffer and Isotype FITCct mixed at 1:50 with FACs 
buffer were added to the PE/FITC column. One hundred µl of FA Cs buffer was added to 
each well in the Neg column. Plates were incubated on ice for 20 minutes. Wells were then 
washed three times with 100 µl of FACs buffer with centrifugation to 2100 rpm. Finally, 50 
µl of FA Cs buffer and 50 µl of 4% formaldehyde was added to each well, plates were 
covered with aluminum foil and fixed overnight at 4° C. Contents of each well were mixed 
r Imrnulon 2, Dynatech, Chantilly, VA 
g Veterinary Medical Research and Development, Pullman, WA 
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and placed in assay tubes containing 0.5 ml F ACs buffer. Samples were submitted to the 
Iowa State University Cell & Hybridoma Facility. FACS analysis of lymphocytes for 
expression of T and B cell surface markers was done on all groups by a Coulter EPICS-XL 
flow cytometere. 
ELISPOT assay 
The ELISPOT assay used to detect the number of IgA, IgG and IgM producing B-
cells was an adaptation of a published method.27 Briefly, antigenic preparations consisting of 
a mycoplasmal membrane specific antigenh (20 µg/ml), a total immunoglobulin preparationi, 
as well as a carbonate/bicarbonate buffer blank, were used to coat 96-well surfactant-free 
mixed cellulose ester membrane microtiter plate~. Separate plates were coated for the 
different antibody isotypes. Plates were refrigerated overnight at 4 ° C, washed three times 
with PBS on the following morning and blocked with 100 µl of sterile 1 % BSA in PBS. On 
the day of sample collection, the isolated cells were counted using a Coulter Counte{, diluted 
to a concentration of 2 X 106 cells/ml and added to the plates at three levels (103, 104 or 105 
cells per well) for each preparation. After overnight incubation at 37° C and washing of the 
wells three times with PBST, anti-swine IgG-APk (1:500), IgM-APk (1:500) and primary IgA1 
(1:1000) antibodies were added, followed by a 30 minute incubation. Plates were again 
h Schering-Plough Animal Health Corp., Kenilworth, NJ 
i Boehringer Mannheim Biochemicals 
i #54510, Millipore Corp., Bedford, ME 
k Kirkegaard & Perry Laboratories, Gaithersburg, MD 
1 Courtesy of Dr. Prem Paul, Veterinary Medical Research Institute, Ames, IA 
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washed three times with PBST. The anti-mouse alkaline phosphatase secondary IgA k (1 :500) 
was added with another 30 minute incubation following. Plates were washed two times with 
PBST, and once with PBS and finally, development of the plates was accomplished using fast 
redd reagenrwith a 60 minute incubation. The number of spots was counted in each well, 
each spot indicating an antibody secreting B lymphocyte. The background was quite dark on 
the initial set of samples collected on day 21, so for the pigs necropsied on days 28 and 29, 
the anti-swine IgG-AP was used at concentration 1:200 rather than 1:500, the anti-swine 
IgM-AP was used at 1:200 rather than 1:500 and the 1° anti-swine IgA was used at 1:500 
rather than 1: 1000. On these two days, BCIP/NBT phosphatase substratek was used to 
develop the spots rather than fast red. At the concentration of 105 cells per well, the spots 
were oftentimes too numerous to count so for our analysis, the wells containing 104 cells 
were used. 
ELISA Protocol 
Antigen was made from MH clone 232 that was isolated from the lung of a pig 
inoculated with strain 11. Microtiter platesf were coated with 100 µl of 10 µg/ml Tween 20 
membrane antigen in carbonate-bicarbonate buffer (pH 9.6) and frozen at -70° C. Plates 
were allowed to thaw at room temperature prior to use. Samples of serum as well as known 
positive and negative controls were diluted 1:50 (20 µl serum into 1 ml buffer) in freshly 
made IX TBSE buffer. The microtiter plates were emptied and washed 3 times with IX 
f Irnmulon 2, Dynatech, Chantilly, VA 
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ELISA wash. One hundred µl aliquots of the diluted samples were added to duplicate wells. 
Positive and negative controls and blank wells containing buffer only were included on each 
plate. 
Plates were covered and incubated for 30 minutes at 37° C. Plates were washed 3 
times with IX ELISA wash. One hundred µl of peroxidase-conjugated rabbit anti-swine 
IgGm diluted 1: 1000 in IX TBSE buffer was added to each well and plates were again 
covered and incubated for 30 minutes at 37° C. Equal volumes of ABTS peroxidase 
substratek and peroxidase solution Bk (H20 2) were mixed and 100 µl was added to each well. 
Plates were incubated at room temperature for approximately 8 minutes and the reaction was 
stopped by adding 100 µl of 1 % SDSct per well. The net OD values were read in an 
automated microplate reader° at 405 nm. Titers were reported by calculating the average of 
the duplicates. Samples were determined to be positive if the sample/positive control ratio 
was greater than 0.60 and suspicious if 0.50 to 0.60. All sera from an individual pig were 
done at the same time on the same microtiter plate to reduce variation. 
Statistics 
Analysis of variance was performed to ascertain differences between treatment 
groups. Pairwise comparisons were performed by least significant difference when the P 
value for the ANOV A model was less than 0.05. 
k Kirkegaard & Perry Laboratories, Gaithersburg, MD 
m Cappel!, Durham, NC 
n Microplate Autoreader EL310, Bio-Tek Instruments 
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Results 
Pigs were evaluated daily throughout the trial for clinical signs including coughing. 
Group 1, the challenged only pigs, exhibited a higher number of coughing days compared to 
groups of unchallenged pigs (Table 3.1). Vaccinated and challenged pigs (Group 2) also 
exhibited coughing although at reduced levels compared to Group 1 but not statistically 
different from non-challenged pigs. 
At necropsy macroscopic lung lesions were only seen in challenged pigs of Groups 1 
and 2 (Table 3.1). Vaccination reduced but did not eliminate the lesions of pneumonia in 
Group 2. Histologic lesions were significantly different between challenged and non-
challenged pigs (p < .005, data not shown), but not between Group 1 (challenged) and Group 
2 (vaccinated and challenged). 
All pigs were seronegative for MH by ELISA on arrival (Titer 1, Table 3.1). At 
challenge (Titer 2) vaccinated pigs in Groups 2 and 3 had higher mean levels of serum 
antibody compared to groups with non-vaccinated pigs. Two weeks following challenge 
(Titer 3), pigs in Group 2, which were vaccinated and also challenged, have much higher 
mean serum antibody than all other groups and this difference is maintained through until 
necropsy (Titer 4). 
Data from the ELISPOT assay is presented as the number of antibody secreting 
cells/10,000 cells (Tables 3.2, 3.3 and 3.4). Statistical analysis of ELISPOT results was only 
done for the response of cells to the membrane antigen and there were no statistical 
differences seen between any of the groups when evaluating the number of cells in the tissues 
secreting IgA, IgG and IgM. Standard deviations were high in all categories. In 
Table 3.1. Mean values for coughing days after challenge, % of lung affected with pneumonia at necropsy, and MH OD antibody 
titers: Titer 1= on arrival, Titer 2= at challenge, Titer 3= 2 weeks post-challenge and Titer 4= necropsy (4 weeks post-challenge) 
Group Cough days % Titer 1 Titer 2 Titer 3 Titer 4 
Pneumonic 
Lun 
1-Chall 4± 3.2a 5.93 ± 3.95a 0.03 ±.Ola 0.04 ± .02b 0.10 ± .05b 0.22 ± .llb 
2-VX/CH 2.4 ± 2.0a,b 2.53 ± 4.25a,b 0.03 ± .01 a 0.31±.17a 0.98 ± .57a 1.03 ± .493 
3-Vacc ob ob 0.03 ± .0043 0.33 ± .17a 0.29 ± .12b 0.18 ± .09b 
4-Neg ob ob 0.04 ± .0093 0.03 ± .Olb 0.04 ± .03b 0.05 ± .02b 
a,b Values in the same column with different superscripts are significantly different (p < .05) 
VX = MH vaccinated, CH = MH challenged 
Positive titer> 0.280 
Table 3.2. Mean number of antibody secreting peripheral blood mononuclear cells per 10,000 cells 
PB MC/Blank PBMCffotal PBMC/Memb 
Groul!___ _ _Jg,A IgM lgG .. IgA _ IgM IgG lgA lgM IgG 
1-Chall 1.3±2.1 3.0±3.1 2.1±2.5 1.3±1.8 9.0±11.6 10.7±13.8 4.7±8.1 25.1±26.3 2.7±3.5 




3.0 ± 2.4 
6.0±5.1 15.7± 17.4 
1.0±0.8 0.7 ±0.5 
1.7 ± 1.2 19.3 ± 23.1 
1.3 ± 1.2 4.0 ± 2.9 
8.7 ± 3.7 
5.0 ± 3.6 
3.3 ± 2.4 
0.7 ±0.9 
38.7 ± 7.4 4.7 ± 1.7 
32.0 ± 25.0 4.3 ± 4.8 
PBMC =peripheral blood mononuclear cells, Blank;:::: negative control, Total =total immunoglobulin preparation, 
Memb = mycoplasma membrane preparation, VX = MH vaccinated, CH= MH challenged, Neg = nonvaccinated/noninfected controls 
°' 00 
Table 3.3. Mean number of antibody secreting lymphocytes in the lung per 10,000 cells 
Lung/Blank Lungff otal Lung/Memb 
Group lgA lgM lgG IgA IgM IgG IgA IgM IgG 
1-Chall 3.6 ± 6.0 5.6 ± 7.4 2.7 ± 3.1 5.4 ± 7.4 13.0 ± 13.3 75.3 ± 83.7 6.3 ± 9.1 22.9 ± 23.1 3.6 ± 4.5 
2-VX/CH 2.4 ± 2.3 3.8 ± 4.0 3.0 ± 3.2 4.3 ± 7.3 10.8 ± 10.8 96.3 ± 87.2 5.1±7.9 27.8 ± 25.7 3.3 ± 4.3 
3-Vacc 2.3±1.7 3.0 ± 4.2 3.0 ± 2.8 4.3±4.7 15.0±17.7 23.0±10.6 5.7 ± 4.5 45.0±9.6 6.7±3.8 
4-Neg 3.0 ± 4.2 5.0 ± 6.4 3.7 ± 4.5 1.7 ± 2.4 8.3 ± 9.7 19.3 ± 16.8 1.7 ± 1.2 36.7 ± 28.0 6.0 ± 5.9 
Blank= negative control, Total= total irnmunoglobulin preparation. Memb = mycoplasma membrane preparation. 
VX = MH vaccinated, CH = MH challenged, Neg = nonvaccinated/noninfected controls 
Table 3.4. Mean number of antibody secreting lymphocytes in the bronchial lymph node per 10,000 cells 
BRLN/Blank BR LN/Total BRLN/Memb 
Group lgA IgM IgG lgA lgM lgG IgA lgM IgG 
1-Chall 1.3 ± 2.1 0.9 ± 1.1 0.9 ± 1.4 2.4 ± 5.2 20.0 ±20.8 44.0 ± 43.4 1.4 ± 2.1 25.3 ± 24.3 1.9 ± 2.2 
2-VX/CH 1.6 ± 2.5 1.5 ± 2.0 0.6 ± 0.9 2.0 ± 2.4 27.6 ± 31.6 40.3 ± 46.9 0.4 ± 0.5 36.5 ± 33.8 2.5 ± 3.5 
3-Vacc 2.3 ± 1.7 4.3 ±4.2 1.7 ± 0.5 1.7 ± 0.9 6.3 ± 2.1 9.7 ± 2.4 2.3 ± 1.9 45.3 ± 18.2 7.3 ± 6.6 
4-Neg 2.0 ± 2.8 1.3 ± 1.2 2.3 ± 3.3 2.0 ± 2.8 11.3 ± 10.9 11.7 ± 8.7 0.7 ± 0.9 44.3 ± 35.9 2.3 ± 2.6 
BR LN =bronchial lymph node cells, Blank= negative control, Total= total immunoglobulin preparation, Memb = mycoplasma 
membrane preparation, VX = MH vaccinated, CH = MH challenged, Neg = nonvaccinated/noninfected controls 
°' \0
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general in the lung, the number of IgA-secreting cells is elevated in all vaccinated and/or 
challenged groups in response to both the total immunoglobulin preparation and the 
membrane antigen compared to controls. Challenged only (Group 1) pigs had the highest 
numbers. Group 1 also had the highest mean number of IgA-secreting cells in the peripheral 
blood in response to the membrane antigen, with some elevation seen in the vaccinated only 
pigs (Group 3). Vaccinated pigs responded best to membrane antigen with IgA and IgG 
secretion in the bronchial lymph node. The total immunoglobulin preparation, however, 
invoked the highest IgG responses in the bronchial lymph node by the challenged only 
(Group 1) and the vaccinated and challenged (Group 2) pigs. IgG secretion was high overall, 
but especially so in all challenged pigs (Groups 1 and 2) in the lung. IgM secretion was 
consistently elevated in response to membrane antigen in all tissues from all groups 
indicating a non-specific mitogenic response. 
There were no significant differences between groups in flow cytometric analysis 
(Tables 3.5 and 3.6; Figures 3.1 , 3.2 and 3.3). However in general, there appeared to be an 
increased mean percentage of B cells in the lungs of all vaccinated and/or challenged groups 
of pigs when compared to controls. Vaccinated pigs (Groups 2 and 3) had slightly higher 
mean percentages of CD4 T cells in the lung tissue. Mean numbers of CD4/CD8 double 
positive T cells in the lung were also elevated in vaccinated and/or challenged groups 
compared to controls. 
Table 3.5. Flow cytometric analysis-mean percentages of B cells and CD4 T cells in tissues 
B cells B cells B cells CD4 CD4 CD4 
Group PBMC BR LN Lung PBMC BR LN Lung 
I-Chall 52.8 ± 14.2 31.3 ± 10.4 36.2 ± 14.9 12.6 ± 5.2 16.9 ± 9.0 10.6 ± 5.4 
2-VX/CH 53.6 ± 12.6 32.5 ± 10.6 40.9 ± 11.4 18.5 ± 5.9 19.5 ± 9.0 15.2 ± 9.8 
3-Vacc 65.3 ± 17.7 25.5 ± 10.8 33.1±9.2 16.2 ± 5.4 15.8 ± 8.4 19.4 ± 5.8 
4-Neg 49.5 ± 21.2 22.3 ± 13.2 22.3 ± 12.9 16.2 ± 2.8 16.2 ± 10.3 9.5 ± 5.4 
PBMC =peripheral blood mononuclear cells, BR LN = bronchial lymph node, VX = MH vaccinated, CH= MH challenged, 
Neg = nonvaccinated/noninfected controls 
Table 3.6. Flow cytometric analysis-mean percentages of CD8 and CD4/CD8 double positive T cells in tissues 
CDS CDS CDS CD4/CDS CD4/CDS CD4/CDS 
Group PBMC BR LN Lung PBMC BR LN Lung 
1-Chall 19.2 ± 2.3 27.0 ± 6.7 29.1±2.2 13.0 ± 2.1 12.0 ± 3.9 12.9 ± 5.0 
2-VX/CH 21.7 ± 2.4 29.4 ± 9.9 31.4 ± 4.7 14.3 ± 3.4 13.8 ± 4.1 13.2 ± 4.0 
3-Vacc 22.4±3.0 31.0±4.7 32.4 ± 1.7 13.2±2.5 11.5 ± 1.0 16.6 ± 4.6 
4-Neg 18.9 ± 5.3 29.2 ± 6.8 36.4 ± 10.6 12.8 ± 3.1 13.1 ± 6.4 7.3 ± 1.9 
PBMC =peripheral blood mononuclear cells, BR LN =bronchial lymph node, VX = MH vaccinated, CH= MH challenged, 
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There were no significant differences in the number of coughing days between the 
challenged groups (Groups 1 and 2) or in any behavioral aspect evaluated during observation 
of the pigs. ELISA results were significant--vaccination plus challenge resulted in the 
highest serum antibody titers although serum titers are not necessarily correlated with 
protection. 
Histologically there were no significant differences in the extent of lymphoid 
hyperplasia when comparing vaccinated pigs to vaccinated plus challenged pigs. Neither 
were there any significant differences in the proportion of lung affected with macroscopic 
pneumonia at necropsy when comparing these two groups although the small sample size 
may preclude detecting significant differences. 
In analysis of cell types using flow cytometry it must be kept in mind that this 
procedure does not measure responses to a specific antigen. Therefore, we measured the 
percentages of cell types in the tissues and were hopeful that if we found differences in 
antibody secretion using the ELISPOT, we could then correlate that to the cell types present 
in the individual tissues. It is also important to realize that in analyzing the lymphocytes of 
the lung by FACs, we are most likely evaluating cells derived from the blood due to the 
extensive vasculature in the lung, except in areas with histologic evidence of mycoplasmal 
lesions in which there would be accumulations of lymphocytes in the tissue. 
We found that the pigs given vaccine only (Group 3) had a slightly higher percentage 
of B lymphocytes in the peripheral blood compared to the other groups. This would serve to 
indicate that vaccination perhaps produces more of a systemic response while infection does 
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not appear to. Mycoplasmosis, being a localized and extracellular infection of the respiratory 
tract, for the most part does not cause systemic interactions although it is thought that while 
pneumonic lesions resolve, blood lymphocytes may be becoming increasingly sensitized and 
specifically activated, perhaps due to the transit of lymph node lymphocytes into the systemic 
circulation after a time.109 Compared to controls, all of our vaccinated and/or challenged pigs 
had an increased percentage of B lymphocytes in the lung, with the highest percentages in the 
vaccinated and challenged pigs, indicating there is preferential stimulation of the local 
humoral immune response. Vaccination of pigs resulted in the highest percentages of CD4+ 
T cells (T helper cells) in the lung. Perhaps immune T cells are thus available to recruit and 
activate macrophages and neutrophils, most likely through cytokines, particularly IL-1 and 
TNF-a, released by the T cells. CD4+/CD8+ T cells were increased in the lungs of 
vaccinated pigs, which would be consistent with the thought that they are resting cells 
associated with memory.123 
Few differences were seen between groups in FACS of the bronchial lymph node 
although the percentage of B cells appeared to be higher in all challenged pigs. We were 
expecting to see some cell-mediated immune responses in the draining lymph nodes, 
especially in unvaccinated/infected pigs. One would expect local lymph nodes to manifest a 
more antigen-specific response than blood lymphocytes. It is possible that responses in 
vaccinated pigs were down-regulated rather quickly, prior to our sampling at 3 and 4 weeks 
post-infection. In a study by Bhogal, MR-vaccinated pigs responded to virulent pathogen 
very quickly after infection, i.e., as early as 4 days post-infection, and this response was 
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down-regulated by 11 days post-infection.19 Even so, both B and T cells appeared to respond 
to MH vaccine antigens. 
In the ELISPOT assay, the mycoplasmal membrane antigen stimulated IgM secretion 
by B-lymphocytes in all of the tissues in all groups. This is a non-specific, IgM stimulation, 
and possibly a superantigen effect, as it would appear that previous sensitization to antigen is 
not required for this response. There was some indication that IgA-secreting B cells in the 
blood of challenged pigs and in the lung of all vaccinated and/or challenged pigs was 
stimulated by the membrane antigen, leading to localized humoral protection which has been 
seen by other researchers. 109 There was minimal IgG response to the mycoplasmal 
membrane antigen in all of the groups, except for the bronchial lymph node response in pigs 
given only vaccine. The lack of IgG response is unexpected especially in the lung of 
experimentally inoculated pigs. Suter describes increasing numbers of lgG-positive cells in 
the lung of MR-infected SPF pigs between weeks 2 and 4 PI.154 Also found in that study 
were increased numbers of lgG-positive cells in the lymph nodes of inoculated pigs at 6 
weeks PI.154 Perhaps in our study, this lack of response is due to either inadequate amounts 
of protein used in the assay, the antigen the preparations contained not being specific enough, 
the antigens were not recognized by the immune system or the membranes themselves may 
not be very immunogenic. 
The secretory response to the total immunoglobulin preparation did not reveal any 
discernible pattern. As a pilot study, we did not have any preconceived notion as to what to 
expect. The swine total immunoglobulin preparation used was an unknown entity with 
respect to specificity and extent of coverage. It was included to attempt to enumerate the B 
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cells present by detecting membrane-bound immunoglobulin. We may have assessed 
response of 20% to 100% of the actual number of B cells present. Thus we determined that 
evaluating the response to the membrane antigen in comparison to the response to the total 
immunoglobulin preparation is of minimal value. 
Conclusion 
Commercial MH vaccines may consist of cell membrane preparations derived from 
organisms grown in culture. Despite the intense use of MH vaccines, in some herds clinical 
disease is still of significance. We found that exposure to MH membranes appears to induce 
a non-mycoplasma specific IgM response, which may or may not be productive and, in some 
cases, could have a superantigen effect and be inhibitory to the immune response. This non-
specific reaction may be part of the reason for failure of vaccines to protect against disease. 
The ELISPOT assay may help identify those MH immunogens which can induce local 
protection and has potential for assessing local humeral immunity and/or cytokine 
production. Infectious challenge resulted in increased percentages of IgA-secreting B cells in 
the peripheral blood in response to the mycoplasmal membrane antigen. In the local lymph 
node there were increased percentages of IgG- and IgM-secreting B cells in response to the 
total immunoglobulin preparation, but not specifically to the membrane antigen. B cells were 
elevated in the local lymph node. Preferential involvement of the local humeral immune 
response over the systemic response following infection of pigs with MH has been suggested 
when it was found that the percentage and total number of B lymphocytes in the lung 
increased following infection. 171 Percentage of B lymphocytes in peripheral blood did not 
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vary following infection. 
Messier previously found no differences in the response of lymphocytes in the blood 
of MH membrane-inoculated pigs compared to control pigs when exposed to mitogens or 
mycoplasmal antigens. 107 He utilized caesarean-derived colostrum-deprived (CD/CD) pigs in 
his study. So-called "germfree" pigs should be able to produce antibody in response to 
antigen, as is seen in germfree rats and mice, although there is probably a pronounced lag 
phase. 182 The lymphocyte population of CD/CD pigs, and notably the plasma cell line, would 
be low in quantity although found to be quite adequate in quality.182 T cell mitogen 
stimulation is largely comparable between germfree and conventional animals. 182 Suter also 
evaluated responses of SPF pigs to MH inoculation. Antigen-specific plasma cells in lymph 
nodes and lung tissue were found as well as immunoglobulins in BALF at 2 weeks PI. 154 
In our study, vaccination alone produced elevated percentages of lgM-secreting B 
cells in the peripheral blood in response to both the total immunoglobulin preparation and the 
membrane antigen. There were also IgA and IgM responses to the membrane antigen in the 
lung as well as an IgG response to the membrane antigen in the lymph node. There was an 
elevated percentage of B cells in the peripheral blood and an elevated percentage of CD4 T 
cells in the lung. 
Vaccination prior to challenge produced elevations in IgA-secreting B cells in the 
lung in response to the membrane antigen and also elevations in IgM- and IgG-secreting B 
cells in the local lymph nodes in response to the total immunoglobulin preparation and, for 
lgM, the membrane antigen also. These pigs showed elevated percentages of B cells in the 
bronchial lymph node and lung. CD 4 T cells were in increased percentages in all tissues. 
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The stimulation of both B and T cells in this experiment suggest that both cellular and 
humoral immune systems are involved in response to mycoplasmal antigens. Vaccination 
prior to MH challenge resulted in high ELISA antibody titers, reduced coughing scores and 
reduced percent of lung exhibiting lesions. Vaccination reduced but did not eliminate 
pneumonia and therefore, does not completely protect against MH challenge. 
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CHAPTER 4. INTERACTION BETWEEN A MODIFIED LIVE VIRUS 
PRRS VACCINE AND A MYCOPLASMA BACTERIN 
A paper prepared for submission to Swine Health and Production 
Authors: T. B. Boettcher, DVM, E. Thacker, DVM, PhD and B. Thacker, DVM, PhD 
Abstract 
The roles of Mycoplasma hyopneumoniae and PRRSV have been identified in the 
acute syndrome known as porcine respiratory disease complex. The disease can be 
characterized by lethary, anorexia, coughing, thumping, poor growth performance and death. 
Natural infection by MR generally results in strong immunity but with the introduction of 
PRRSV, there is not enough time for protection to develop and the pathogens work in consort 
to produce more severe clinical signs. Vaccination against these pathogens has become 
commonplace but there seems to be a higher incidence of clinical disease even with 
vaccination. The possibility of vaccine interference led to this research trial, which was 
designed to investigate the effect of vaccination with a modified live virus PRRS vaccine on 
the ability of the pig to respond immunologically to a MR bacterin. Pigs were assigned to 
one of 8 treatment groups, four of which were vaccinated with PRRS vaccine on day 0. Of 
those vaccinated for PRRS, two were also vaccinated for MR on days 8 and 22 and one of 
those was subsequently challenged with MR on day 36. Of the two groups not receiving MR 
vaccine, one group was also MR-challenged on day 36. Four groups did not receive PRRS 
vaccine, two of those received MR vaccine, two did not. One group from each of the latter 
two groups was MR-challenged. 
There were no group differences in growth performance. Serotesting indicated 
significantly lower PRRS antibody titers in pigs receiving both PRRS and MR vaccines 
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compared to those receiving PRRS vaccine alone. l\1H titers were highest in pigs receiving 
both vaccines and l\1H challenge. Vaccination with a 11L V PRRS vaccine did not interfere 
with immune responses to l\1H bacterin administration and appeared to augment antibody 
levels. Assay for antibodies in bronchoalveolar lavage fluid at necropsy, 28 days following 
challenge, indicated high IgA levels in l\1H-vaccinated and challenged pigs. IgG production 
was highest in pigs receiving both vaccines and also challenged. An ELISPOT assay for 
detection of interferon-gamma producing cells responding to l\1H membrane antigen revealed 
that vaccinated pigs demonstrated a higher response rate, especially in the blood. 
Introduction 
Mycoplasma hyopneumoniae (MH) is the primary agent of enzootic pneumonia of the 
pig. 134 Generally seen in the past as a mixed infection with Pasteurella multocida, Haemophilus 
parasuis and/or Actinobacillus pleuropneumoniae, recent estimates are that 80% of slaughter hogs 
have lesions resulting from MH infection.134 Although clinical disease is generally mild in a· herd 
and there is low mortality, infection may result in high morbidity characterized by chronic 
coughing. Of major importance recently is this organism's key role in the new syndrome 
labeled porcine respiratory disease complex (PRDC) wherein multiple infectious agents are 
involved in producing acute clinical disease consisting of fever, anorexia, coughing, dyspnea 
and tachypnea along with depressed growth rate and feed efficiency generally late in the 
finishing phase.71 Primary and/or secondary bacterial pathogens, such as Actinobacillus 
pleuropneumoniae, Pasteurella multocida, Streptococcus suis and Actinomyces pyogenes as 
well as pathogenic viral agents, including swine influenza virus (SIV) and porcine 
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reproductive and respiratory syndrome virus (PRRSV) have been isolated or identified in 
respiratory disease outbreaks in large finishing units.71 The recent resurgence of MH seems 
to coincide with the adoption of multiple-site production systems perhaps resulting in the 
creation of sub-populations of naive animals within infected herds that are susceptible to 
infection. The most commonly identified pathogens at the Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL) in recent cases of PRDC have been MH, PRRSV and 
SIV.11 
Successful strategies for controlling respiratory disease due to MH, SIV and PRRSV 
have focused on vaccination and management. Age segregated rearing and/or movement of 
pigs all in-all out by room or building have been effective in reducing disease in general. 
Even so, many producers have come to rely on vaccination for effective control of clinical 
respiratory disease. Most commonly, modified-live virus PRRS vaccines, which must infect 
the animal for the immune response to develop, are used. Mycoplasma vaccines are killed 
bacterins that generally require two doses to be effective. Label recommendations for these 
bacterins often read to give the first dose at 1-3 weeks of age followed in two weeks by a 
booster dose. 
Recently, there has been a rriajor increase in cases of pneumonia at the Iowa State 
University Veterinary Diagnostic Laboratory attributed to MH and, with the frequent finding 
of a concurrent PRRS virus infection, concern has shifted to the apparent failure of the l\1H 
vaccines to protect against clinical disease. The originating herds may be practicing a 
scheduled mycoplasma vaccination program and they may also be using a strategically-timed 
PRRSV vaccine. Commonly the PRRSV vaccine is given prior to the mycoplasma bacterin 
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and such was the regimen followed in this study. Our concern is that the timing of 
administration of the vaccines is crucial to investigating their interactions and the efficacy of 
each vaccine. 
Clinical effects of infection with Porcine Reproductive and Respiratory 
Syndrome Virus 
Abortions, increased premature and weak piglets, as well as mummified fetuses, early 
embryonic death and infertility may be seen in the breeding herd infected with PRRSV.177 
Sows may exhibit anorexia, lethargy, or with atypical PRRS, 10 to 30 percent of animals may 
abort and there may be high sow mortality.24 In other infected herds, there may be no clinical 
signs, especially after the immunity has stabilized in the herd and the virus is not being 
actively shed.86 Other pathogens may be involved in the progression of disease due to the 
presumed loss of an effective local cellular immunity resulting from PRRSV infection of, and 
lysis of, pulmonary alveolar macrophages which are a major defense mechanism in the 
respiratory tract.30 However, a report of studies on dual infections of PRRSV followed in 
one week by an H3N2 strain of SIV or PRRSV followed by APP in SPF pigs concluded that 
previous PRRSV infection of the respiratory tract does not necessarily enhance the severity of 
secondary infections of the respiratory tract. 128 It is thought that PRDC is initiated by 
PRRSV with bacteria serving as secondary infections after respiratory defenses are inhibited. 
Recently, however, research has indicated that MH infection actually increases the duration 
and severity of PRRSV-induced pneumonia. 162 
PRRS virus transmission is most commonly from pig-to-pig although there may be 
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airborne spread.86 Semen, blood, and saliva of infected swine are known to transmit 
infection.32 PRRSV can be shed in urine for< 2 weeks while saliva and semen can contain 
virus for> 6 weeks after infection.32 Isolation of infected animals is deemed critical for 
containment of the virus. There is evidence of transplacental exposure as well, both with 
virulent field and attenuated vaccine viruses.69•86 
The virus is able to persist for an extended period of time via continuous, but often 
limited replication in immune-privileged sites or specific subpopulations of cells. 16•86 
PRRSV is most readily isolated from either lymph nodes or tonsils of pigs and also the testes 
of boars, although how it persists is not known. 16 
Clinical effects of PRRSV + Mycoplasma hyopneumoniae infection 
Porcine reproductive and respiratory syndrome virus infects phagocytic cells 
including pulmonary alveolar macrophages, a frontline defense in the pig lung. 160 Since 
macrophages present foreign proteins to the immune system, anything affecting their function 
may alter (presumably suppress) the response of the immune system to invading organisms 
including bacteria and viruses. Decreases in the percentages of IgG-secreting B cells and 
CD4-positive T cells were seen in the peripheral blood of PRRSV-infected pigs at 3 and 6 
days PI in one study. 160 
Proper use of modified-live virus vaccines results in infection of the vaccinated 
animal and minimal to mild clinical disease. PRRSV vaccine can induce lethargy, anorexia 
and fever in pigs along with generalized lymphadenopathy and mild pneumonia.69 The 
vaccine virus can be demonstrated in alveolar and intravascular macrophages. 
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A study was conducted by Van Alstine to determine what effects PRRSV infection 
had on the severity of MH infection in young pigs. Three-week-old pigs were either 
inoculated with PRRSV, PRRSV + MH or MH alone. The PRRS virus was given 
intranasally ·one week before the intratracheal MH challenge. One month following MH 
challenge all pigs were necropsied. These researchers did not find any significant differences 
in coughing days or macroscopic and/or microscopic lung lesions and MH was isolated from 
all MH challenged pigs. 168 
More recently, Thacker et al.25 found that MH infection drastically influenced the 
course of PRRSV pneumonia. Their study used 140, 6-week-old pigs. Pigs infected with 
both pathogens had significantly prolonged and severe pneumonia exhibiting PRRS-like 
macroscopic and microscopic lesions as well as more extensive microscopic lesions typical 
of MH.25 Groups of pigs were inoculated with MH 21 days prior to, concurrent with or 10 
days following PRRSV infection. All pigs given PRRSV were seropositive by 10 days post-
infection. None of the pigs challenged with MH developed detectable MH antibodies during 
the study. Necropsies were conducted at 3, 10 and 28 days post-mycoplasma infection. At 
the 28 day necropsy, in pigs given both pathogens at the same time there were macroscopic 
lesions consistent with PRRSV infection involving approximately 43% of the lung while pigs 
given PRRSV 10 days prior to MH had approximately 30% lung involvement.25 In either 
group lesions due to MH constituted approximately 7.5% of the lung. When MH was given 
21 days prior to PRRSV lung involvement attributable to PRRSV was approximately 16% 
with MH lesions of about 3.5%. Pigs given only PRRSV on day 0 had minimal lung 
involvement (approximately 0.75%) at the 28 day necropsy.25 Generally, MH vaccinated 
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pigs subsequently challenged with MH develop less than 2% pneumonic lesions, however, in 
another study, MH vaccinated pigs co-infected with MH and PRRSV developed almost 6% 
pneumonia lesions thus there appears to be some potentiation of mycoplasmal infection as 
well.163 
Mycoplasma vaccination 
Commercial killed MH bacterins using aluminum-hydroxide adjuvanted or oil-in-
water emulsions of whole-cell, inactivated cultures have been available for a number of years 
and although they have been shown to reduce the severity of pneumonia, they do not prevent 
colonization or eliminate infection. 164 Notorious for being poor immunogens, a major 
difficulty with mycoplasmal vaccines is the identification and separation of the appropriate 
antigen(s) and then guiding the response toward the populations of lymphocytes that need to 
be stimulated in order to provide protection. Mucosa! antibodies against mycoplasmal 
antigens in the lung of cattle and mice have been shown to be somewhat protective.77 
Seroconversion with detectable antibody titers after vaccination is often used as a 
measure of efficacy. However with MH, the factors that determine the effectiveness of 
vaccination are incompletely understood. Common environmental stresses that pigs are 
exposed to daily can impact the response of the pig's immune system to MH vaccine. Age, 
nutritional status, and environmental conditions including temperature, humidity, pollutants 
and toxins are factors to be considered. 
To evaluate whether experimentally induced stress could influence the production of 
antibody to MH, Wallgren immunized 6-month-old pigs three times with antigen.(days 1, 25 
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and 60). On days 63 to 70 they intramuscularly injected four of the six pigs with 60 USP 
units porcine ACTH per 100 kg body weight twice daily. They indicated that in three of the 
four pigs high, but physiological, levels of cortisol maintained for at least 7 days were 
necessary before any depressions in MH antibody production, response to mitogen 
stimulation or production of IL-2 were noted. 172 The results demonstrate that there may be 
stress-mediated delays in response to infection or vaccination and that exogenous or 
endogenous steroid compounds may negatively impact immune responsiveness. 
Clark investigated whether experimental inoculation of or contact exposure to MH, 
with or without the environmental factors of presence of ammonia and temperature variation, 
could induce pneumonia and reduce growth rate in na'fve pigs. Ammonia was added 
continuously to the room air to mimic the ammonia concentration detected in a local 
finishing building. Room temperatures were adjusted twice daily to mimic diurnal variations. 
They concluded that MH exposure plus environmental insults had no additional detrimental 
effect than MH exposure alone.40 No differences were seen in growth rates. In contrast, 
Pointon detected higher levels of respiratory disease in herds that had high levels of 
ammonia.126 
Vaccine labels of MH vaccines usually recommend administering piglets the first 
dose intramuscularly at one to three weeks of age, with a booster dose given in two weeks. 
The vaccine can also be administered to pregnant sows, resulting in higher antibody titers in 
the colostrum. Pigs suckling vaccinated sows show antibody titers in serum that may last 
past 8 weeks of age. 113 
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PRRS Vaccination 
A modified live virus vaccine for use in pigs between three and 18 weeks of age was 
introduced in 1994 for immunization against the respiratory form of PRRS. In 1996 the 
USDA approved the use of this vaccine in non-pregnant breeding age females. 69 Vaccine 
virus can be found (and thus shed) in pigs at varying times post-vaccination in oronasal 
secretions, urine, feces and semen.69 Post-vaccination viremias are supposedly shorter in 
older animals (1-3 weeks in 5 month old pigs versus approximately 4 weeks in 3-4 week old 
pigs).69 Sows given vaccine virus orally or vaccinated intramuscularly during gestation, 
although not label or approved uses, have been known to farrow viremic pigs.70 
Currently there are several modified live preparations as well as one killed 
commercial vaccine available for control of PRRSV. Protective immunity against PRRSV 
takes a relatively long time to build and is primarily a cell-mediated response because of the 
intracellular location of the pathogen. It is recommended that vaccination should be 
performed long before challenge and it is also recommended that pigs are not to be 
vaccinated in the face of an outbreak. 
Researchers have reported differing results concerning vaccination of uninfected 
weaned pigs with MLV PRRSV vaccine. Henry et al determined that use of a MLV vaccine 
(RespPRRS™) resulted in suppression of growth rate for 1-2 weeks after weaning and 
vaccination.75 Four experiments conducted by Thacker et al , however, using a different ML V 
vaccine (Prime Pac PRRS+™) showed no significant difference in average daily gain 
between vaccinated and non-vaccinated pigs. 160 Groups of pigs from PRRSV-free herds as 
well as from endemically-infected herds were involved in the latter experiments. 
90 
Detrimental effects of PRRSV vaccination have not been fully assessed. Gorcyca et 
al evaluated the safety of a modified live virus PRRS vaccine in nai"ve pregnant gilts. At two 
days after exposure, the body temperature of vaccinated animals was elevated by 0.5° C 
versus an elevation of 1.0° C in animals exposed to a field virus.69 There were transient 
reductions in white blood cell counts in both groups although animals given the field strain 
manifested more dramatic effects.69 Also investigated were safety at !OX effective dose and 
safety of repeated doses (3 doses total). There was a significant increase in the white blood 
cell counts of vaccinated animals after the second dose of vaccine but there were no 
detrimental effects noted.69 In another study, PRRSV vaccination using a modified live virus 
vaccine did not affect average daily gain in a commercial offsite nursery.147 
Vaccine usage may be questionable in light of results of a study assessing MH and 
PRRSV co-infection. The use of PRRSV vaccine did not reduce lesions associated with 
PRRSV pneumonia and did not protect against the MR-induced potentiation of PRRSV 
pneumonia.164 The strain of virus used for challenge in this study was not the same as the 
parent strain of the vaccine virus. The antigenic makeup of the virus apparently differs 
geographically making cross-protection an important factor to be assessed. One must also 
consider that reversion to virulence of an RNA virus is always possible with a ML V vaccine, 
assuming a mutation rate of one in 105 replications.94 
Objective 
The objective of this study was to investigate the effect of vaccinating with a 
modified live porcine reproductive and respiratory syndrome virus vaccine on the ability of a 
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Mycoplasma hyopneumoniae bacterin to protect against experimental challenge with MH. 
Researchers have found that MH infection potentiated the PRRSV-induced pneumonia.163•164 
We hypothesize that vaccination with a modified live PRRSV vaccine will interfere with the 
local respiratory and perhaps systemic immune responses to vaccination that are required for 
protection from M. hyopneumoniae. We compared in vitro production of interferon and in 
vivo production of local and systemic antibodies in response to vaccination with PRRSV 
and/or MH as well as experimental MH challenge. 
Experimental design and methods 
Sixty-nine PRRSV- and mycoplasma-free pigs were randomly assigned to 8 treatment 
groups. The protocol design is summarized in Table 4.1. Upon arrival the pigs were 
randomly placed on raised decks in four separate isolation rooms according to vaccination 
protocols. On day 19 all pigs were moved into pens with solid concrete floors. On day 42 
some groups of pigs were divided into two rooms to allow for adequate space requirements. 
Four pigs were lost during the study, two being euthanized because of lameness problems, 




A modified live virus PRRS vaccine a was administered according to the 
manufacturer's recommendations on day 0 to Groups 1, 3, 5 and 8. 
A killed mycoplasma bacterinb was administered according to manufacturer's 
recommendations on day 8 to Groups 2, 4, 6 and 7 with a booster dose given on day 22. 
Inoculum 
Ten ml of a 1: 100 dilution of 10% crude lung homogenate of Mycoplasma 
hyopneumoniae LI31 c was administered intratracheally as previously described to Groups 5, 
6, 7 and 8 on day 36.172 
Clinical evaluations 
Blood samples were obtained from all pigs the day after arrival (day -8) and the pigs 
were also weighed, tagged and injected with 0.5 ml of a broad-spectrum antibioticd 
intramuscularly in the right side of the neck at this time. Serum samples were tested for MH 
and PRRSV antibodies by ELISA to establish seronegative status. A commercial test kit was 
used for PRRSV serotesting.e The MH ELISA protocol was as established by Dr. R. F. 
Ross Lab, VMRI, Ames, Iowa.125 All pigs were seronegative for MH and PRRSV 
antibodies. 
a RespPRRS/Repro™, Serial No: JA-445B-196, Exp. 18 Sep 99, NOBL Laboratories, Sioux Center, IA 
b Respisure™, Serial No: 157815070, Exp. 6 Jan 00, Pfizer Animal Health Inc., Exton, PA 
c Courtesy of Dr. Richard Ross Laboratory, Veterinary Medical Research Institute, Ames, IA 
d Excenel™, Lot #20BDU, Exp. 02/1999, Pharmacia & UpJohn, Kalamazoo, MI 
e HerdChek: PRRS®; Serial #09635-588DR. Exp 4-May-1999; IDEXX Laboratories Inc., Westbrook, MA 
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All pigs were weighed on day 0 and pigs averaged 15.6 lbs. Four groups 
(Groups 1, 3, 5 and 8) of pigs were immunized against PRRS virus on day 0. Rectal 
temperatures of four pigs from each group (1 to 8) were measured on the day of and every 
other day for 10 days after PRRS vaccination. A PRRSV clinical score as previously 
described by Halbur et ai73 was applied to the same pigs: 
0 = normal 
1 = mild dyspnea and/or tachypnea when stressed 
2 = mild dyspnea and/or tachypnea when at rest 
3 = moderate dyspnea and/or tachypnea when stressed 
4 = moderate dyspnea and/or tachypnea when at rest 
5 = severe dyspnea and/or tachypnea when stressed 
6 = severe dyspnea and/or tachypnea when at rest 
Stress was induced by the pig handler holding the pig under his arm and talcing the rectal 
temperature for approximately 30-60 seconds. Pigs were evaluated daily for abnormal 
clinical signs including evidence of changes in appetite, respiratory rate, coughing or 
behavior. Pigs were weighed periodically throughout the trial and at necropsy to evaluate 
growth rate. They were allowed ad libitum access to feed. Blood samples were obtained at 
various times during the trial for evaluation of PRRSV and MH antibody levels as well as 
PRRSV viremia. Serum samples were maintained at -70° C until the end of the trial at which 
time the assays were performed. 
The first necropsy of 16 pigs was performed on day 35. All pigs due to be challenged 
were inoculated intratracheally on day 36. All remaining pigs were necropsied on one of 
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Table 4.1. Experimental design. 
Grou.Q PRRS V x Mhyo Vx Booster Challenge Necro2sy day(# of .Qigs} 
1 DayO Day 8 Day22 None Day35 (4) 
Day61 (2) 
Day63 (2) 
2 None Day 8 Day22 None Day35 (4) 
Day 61 (2) 
Day 62 (3) 
3 DayO None None None Day35 (4) 
Day61 (2) 
Day63 (2) 
4 None None None None Day35 (3) 
Day 61 (2) 
Day 62 (3) 
5 DayO Day8 Day22 Day36 Day61 (3) 
Day63 (4) 
6 None Day8 Day22 Day36 Day 61 (4) 
Day 62 (5) 
7 None None None Day36 Day 61 (4) 
Day 62 (5) 
8 DayO None None Day36 Day61 (2) 
Day63 (5) 
three days at 26-28 days post-challenge, at the time when mycoplasma lesions may be 
considered to be at close to their maximum intensity. 
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Necropsy 
Four pigs from each of Groups 1 through 4 were necropsied on day 35 to establish 
baseline normal levels of antibodies in bronchoalveolar lavage fluid using ELISA and for 
interferon-y production by cells in the blood, bronchial lymph node, and inguinal lymph node 
using the ELISPOT assay. Pigs were anesthetized using sodium pentobarbital IV and 
euthanized by exsanguination. The right rib cage was reflected and the lungs removed and 
evaluated for gross lesions. Lesions consistent with mycoplasmal pneumoniae (dark-red to 
purple firm areas) were sketched on a standard lung diagram. The proportion of lung surface 
with lesions was determined from the diagram using an image analyzing system.f PRRSV 
lung lesions were scored using a system developed by Halbur, et al.72 This scoring system is 
based on the approximate volume that each lobe contributes to the entire lung: the right and 
left apical lobes and the right and left cardiac lobes contributing 10% each, the intermediate 
lobe contributes 5%, and the right and left diaphragmatic lobes each contribute 27.5%. Each 
lobe is assigned a score that reflects the percentage of it affected by pneumonia and these 
scores are then used to calculate the total lung pneumonic score. There were no discernible 
PRRSV lesions in any of the pigs at necropsy. 
Blood, bronchial lymph node, and inguinal lymph node samples were collected for 
analysis of interferon-y production. The lung was not sampled as it was assumed that the 
uninfected lung would simply register the same values as the peripheral blood making its 
passage through the capillary beds. Bronchoalveolar lavage was performed on each lung 
using 50 ml of :rvffiM media containing antibiotics (9 µg/ml gentamycin, 100 U/ml penicillin 
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using 50 ml of l\1EM media containing antibiotics (9 µg/ml gentamycin, 100 U/ml penicillin 
G, and 100 µg/ml streptomycin). Bronchoalveolar lavage fluid was analyzed for levels of 
MB-specific IgA, IgG and IgM antibodies by ELISA. Samples of lavage fluid were frozen at 
-70° C to facilitate virus isolation, if deemed necessary. Lung samples were obtained from 
areas with macroscopic lesions, if present, for culture of MH and for FA testing. 
Lymphocyte isolation 
Mononuclear cells were isolated from each of the tissue samples by direct differential 
centrifugation over ficoll Histopaqueg 1077 as previously described by Thacker.162 For 
blood, ten ml of heparinized peripheral blood was added to an equal volume of PBS and then 
layered onto 9 ml of ficoll. For lung and lymph nodes the tissues were minced and forced 
through a sterile wire mesh, rinsed with PBS and diluted to 20 ml with PBS. The cells were 
then layered onto 20 ml of warmed ficoll . Ficoll/tissue samples were centrifuged for 30 
minutes at 2500 rpm. The cloudy leukocyte interlace layer was removed using a glass 
pasteur pipette, transferred into 2 tubes and each tube was diluted to 12 ml with PBS for 
washing. Tubes were centrifuged at 1500 rpm for 10 minutes and the supernatant discarded. 
Cells were combined into one tube, resuspended in 10 ml PBS and centrifuged at 1000 rpm 
for 10 minutes. Cells were washed once more in the latter fashion. Peripheral blood samples 
were treated with 1 ml of sterile water followed by 3 ml of sterile saline and then 5 ml of PBS 
to lyse contaminating erythrocytes. After a final wash, the supernatant was discarded and the 
g Sigma Chemical Co., St. Louis, MO 
97 
cells were suspended in 2 ml of RPMI-1640 complete media (RPMig, 10% fetal bovine 
serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine). 
ELISPOT for porcine interferon-y 
An ELISPOT assay27 was first developed to quantitate specific antibody production 
by B lymphocytes. It was later modified for the detection of cytokine-secreting cells. The 
assay was conducted using lymphocytes isolated as described from peripheral blood or 
lymphoid tissues.162 For each tissue from each pig the concentration of a 100 µ1 sample of 
cells suspended in RPMI was determined using a Coulter Counter. All samples were 
standardized to a final concentration of 2 x 106 cells/ml of RPMI. 
The technique is briefly described as follows: using microtiter platesh, wells were 
coated with 50 µ1 of monoclonal capture antibody anti-IFN-y (P2G10)i at 1:2000 in 
bicarbonate buffer (0.05 M pH 8.2) under a sterile hood. A 7 .5 µ1 aliquot of P2G 10 was 
mixed in 15 ml of buffer for use on 3 plates. Plates were incubated overnight at 4° C. Prior 
to use they were washed three times with sterile PBS. Blocking was accomplished by adding 
100 µI/well of sterile RPMI + 10% FCS. Plates were incubated for two hours at 37° C with 
5% C02 in a humid environment. Wells were emptied and 100 µ1containing2 x 104 cells 
(isolated mononuclear cells) in RPMI + 10% PCS± antigen/mitogen was added to each well. 
There were three wells for mycoplasma antigen, two wells for no-stimulation control and one 
h Immulon 2, Dynatech, Chantilly, VA 
i Courtesy of Dr. Frederico Zuckerman, Univ. of Illinois, Champaign/Urbana 
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well for Con A mitogen positive control for each tissue-e. g. lung, bronchial lymph node, 
inguinal lymph node and blood for each pig. Con A primary stock solution containing 4.0 
mg/ml was diluted to 400 µg/ml by adding 100 µl stock to 900 µl RPMI. This was further 
diluted to 10 µg/ml by adding 375 µl of primary stock solution to 15 ml RPMI for use on 
plates. Concentration of stock l\1H antigen was 3.7 mg/ml diluted to 40 µg/ml by adding 319 
µl of stock to 29.5 ml RPMI. RPMI was used as a no stimulus control. Plates were placed in 
an incubator at 37° C with 5% C02. Plates are sensitive to handling at this time so they must 
not be moved after placement in the incubator. After 20 hours, the plates were washed three 
times with a fresh solution of PBST. Fifty µl of a 1 :400 dilution of rabbit anti-swine IFN-'/ 
(50 µl of stock solution in 19.7 ml PBST) was added to each well to detect the captured IFN-
y and plates were placed in a dry incubator at 37° C for one hour. Plates were washed three 
times with PBST and then 50 µl of a 1:1000 dilution of donkey anti-rabbit IgG-HRJli, 
prepared by diluting 26.5 µl of stock in 26.5 ml PBST, was added to each well. Plates were 
again incubated one hour at 37° C, washed three times with PBST. Finally, 75 µl of TMB 
Membrane Peroxidase Substrate (3,3',5,5'-tetramethylbenzidine)k was added to each well to 
develop the reaction. Spots were allowed to develop for 10 minutes and stopped by addition 
of distilled water. Spots were counted under a dissecting scope. 
i Jackson Immunoresearch Lab., West Grove, PA 
k Kirkegaard & Perry Laboratories, Gaithersburg, MD 
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ELISA for serum and bronchoalveolar lavage fluid antibodies 
Serum was kept frozen at -70° C until after the trial was concluded at which time 
samples were thawed for testing. All samples were assayed for antibodies to MH by ELISA 
as previously described. 125 Briefly, microtiter plates' previously coated with 100 µl of 10 
µg/ml Tween 20 antigen in carbonate-bicarbonate buffer (pH 9.6) and frozen at -70° C were 
allowed to thaw at room temperature. Samples of serum as well as known positive and 
negative controls were diluted 1:50 by adding 20 µl serum to 1 ml lX TBSE buffer (lX 
TBSE buffer must be made fresh each day). The microtiter plates were emptied and washed 
3 times with lX ELISA wash. A 100 µl aliquot of the samples was added to duplicate wells 
along with positive and negative controls and blank wells containing buffer. Plates were 
covered and incubated for 30 minutes at 37° C. Plates were washed 3 times with lX ELISA 
wash. One hundred µl of peroxidase-conjugated rabbit anti-swine IgGm diluted 1: 1000 in lX 
TBSE buffer was added to each well and plates were again covered and incubated for 30 
minutes at 37° C. Equal volumes of ABTS peroxidase substrate0 and peroxidase solution B0 
(H20 2) were mixed and 100 µl was added to each well. Plates were incubated at room 
temperature for approximately 8 minutes and the reaction was stopped by adding 100 µl of 
1 % SDSg per well. The net OD values were read in an automated microplate reader0 at 405 
nm. Known positive and negative sera were included as controls for each plate. Titers were 
reported by calculating the average of the duplicates. Samples were determined to be 
1 Immulon 2, Dynatech, Chantilly, VA 
m Cappell, Durham, NC 
° Kirkegaard & Perry Laboratories, Gaithersburg, MD 
g Sigma Chemical Co., St. Louis, MO 
0 Microplate Autoreader EL310, Bio-Tek Instruments 
100 
positive if the sample/positive control ratio was greater than 0.60 and suspicious if 0.50 to 
0.60. All sera from an individual pig were done at the same time on the same microtiter plate 
to reduce variation. 
Seruin was assayed for antibodies to PRRSV using a commercial kite. Results were 
read as optical density values on a spectrophotometer at a wavelength of 630 nm. Cut-off 
value for positive samples was a sample/positive control ratio of 0.40 or greater. 
MH antibody levels in bronchoalveolar lavage fluid were evaluated using an ELISA 
protocol established by T. F. Young. Preparation of the microtiter plates containing MH 
antigen was as described for serum ELISA. Separate plates were utilized for each antibody 
(lgA, IgG and IgM). Bronchoalveolar lavage fluid was tested undiluted. Briefly, 100 µI of 
sample was added to duplicate wells. Negative control wells containing PBS were included 
on each plate. Plates were incubated for 30 minutes at 37° C and then washed three times 
with IX ELISA wash. Conjugates were added, e.g. 100 µI of conjugated 1:5000 goat anti-
swine lgA-alpha-HRPOP, 100 µI of conjugated I:500 goat anti-swine lgG (gamma) 
peroxidasek and 100 µl of conjugated I:500 goat anti-swine lgM (µ) peroxidasek. Plates were 
incubated for 30 minutes at 37° C, washed three times with IX ELISA wash and then 100 µl 
of substrate (equal volumes of ABTS peroxidase substrate and peroxidase solution B 
[H20 2])k was added to each well . Plates were incubated at room temperature for 6-10 
minutes depending on the particular antibody and the reaction was stopped by adding 100 µI 
of I% SDSk to each well. Optical density values were determined at a wavelength of 405 
P Bethyl Laboratories Inc. , Montgomery, TX 
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nm on an automated microplate reader0 • 
Statistics 
Analysis of variance was performed in Statistix® (Analytical Software, Tallahassee, 
FL) to ascertain differences between treatment groups. An F-statistic (P < 0.05) was 
performed to evaluate differences between treatment groups. Pairwise comparisons were 
performed by least significant difference when the p value for the ANOV A model was less 
than 0.05. 
Results 
Each room and/or group of pigs was evaluated for growth performance by serial 
weighings (Table 4.2). The groups did not vary significantly in their mean weight gain. 
Lung lesions compatible with MH infection were significantly elevated in pigs which 
were not vaccinated for MH and received challenge inoculum (Table 4.3). There was no 
difference between PRRS vaccinated and non-vaccinated pigs. Bronchial lymph node 
weights at necropsy showed a similar pattern. 
PRRS serology (Table 4.4) was done on all pigs at days -8, 14 and 35 
(first necropsy of 15 pigs) or 62 (second necropsy). PRRS vaccination of Groups 1, 3, 5 and 
8 occurred on day 0. By day 14, all PRRS-vaccinated pigs had seroconverted while none of 
the non-vaccinated pigs had a titer. On day 62, all PRRS-vaccinated pigs still had positive 
titers. 
Local antibody production detected in bronchoalveolar lavage fluid (BALF) by 
0 Microplate Autoreader EL310, Bio-Tek Instruments 
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Table 4.2. Average weight gain (lbs.) per group. 
Groue VX/CH Dar35 Dar so Dar62 
1 P,M 42.91±4.85 77.23 ± 4.37 102. 73 ± 7.27 
2 M 43.56 ± 4.51 71.36 ± 4.85 93.76 ± 6.40 
3 p 46.61 ± 3.31 74.57 ± 3.92 92.57 ± 7.53 
4 None 45.41±4.61 69.20 ± 5.08 89.20 ± 4.92 
5 P,M,CH 44.08 ± 6.13 70.36 ± 7.97 91.21±10.79 
6 M,CH 44.27 ± 3.65 70.80 ± 6.15 90.80 ± 6.49 
7 CH 40.87 ± 3.64 66.98 ± 6.89 87.25 ± 9.57 
8 P,CH 44.31±5.15 69.44±11.1 89.44 ± 12.17 
P = PRRS vaccine, M = MH vaccine, CH = MH challenge 
ELISA is shown in Tables 4.5 (first necropsy) and 4.6 (second necropsy). Results 
demonstrate that, as expected, significantly higher levels of IgA were found in pigs that were 
both mycoplasma vaccinated and challenged compared to all other groups. IgG levels in 
BALF were highest in MH vaccinated and challenged pigs. 
All but one of the MB-inoculated pigs was culture positive. The non-challenged pigs 
Table 4.3. Mean weights of bronchial lymph nodes (lyn wt) and mean percentages of lungs 
(lesions) affected by macroscopic mycoplasmal pneumonia at final necropsy. 
Group N VX/CH LYNWT(g) LESIONS(%) 
1 4 P,M 4.81 ± l.96b ob 
2 5 M 6.29 ± l.64a,b 0.06 ± O.lOb 
3 4 p 6.25 ± 2.42a,b ob 
4 5 None 5.03 ± l.17b 0.20 ± 0.38b 
5 7 P,M,CH 8.46 ± l.87a 0.79 ± 0.47b 
6 9 M,CH 8.45 ± l.61a 0.16 ± 0.22b 
7 9 CH 8.57 ± 2.62a 4.60 ± 3.09a 
8 7 P,CH 8.66 ± 2.80a 5.35 ± 5.22a 
N = number of pigs 
P = PRRS vaccine, M = MH vaccine, CH = MH challenge 
a,b Within each column, values with different superscripts are significantly different (p<.05) 
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Table 4.4. Mean PRRSV sample/positive control ratios (SIP). 
Grou2 VX/CH Da~-8 Da~ 14 Da~35 Da~62 
1 P, M 0.001±0.004b 0.736 ± 0.449a 1.670 ± 0.389a 1.063 ± O. ll 7b 
2 M ob 0.002 ± 0.005b 0.004 ± 0.008b 0.012 ± o.02oc 
3 p ob 0.932 ± 0.520a 1.591 ± 0.453a 1.624 ± 0.341a 
4 None 0.001±0.003b 0.012 ± 0.023b 0.009 ± 0.015b 0.019 ± 0.021 c 
5 P,M,CH 0.047 ± 0.047a 0.687 ± 0.261 a NA 1.014 ± 0.215b 
6 M,CH 0.009 ± 0.015b 0.003 ± 0.006b NA 0.021 ± 0.033c 
7 CH 0.020 ± 0.032b ob NA 0.015 ± 0.028c 
8 P,CH 0.016 ± 0.024b 0.806 ± 0.279a NA 1.478 ± 0.225a 
P = PRRS vaccine, M = MH vaccine, CH = MH challenge, NA = not applicable 
a,b,c Within each column, values with different superscripts are significantly different 
(p<.05). 
had no positive cultures. 
FA was done on frozen sections of lung taken from all pigs at necropsy. Sensitivity 
was not high since 13 of the challenged pigs had negative FA tests (data not shown) although 
they were positive on culture. 
Interferon-y production by mononuclear cells in the different tissues detected by 
ELISPOT assays is shown in Tables 4.7 and 4.8. At the first necropsy, pigs in Group 1 
that received both PRRS and MH vaccines demonstrated the highest numbers of secreting 
Table 4.5. Mean Optical Density (OD) values for Mycoplasma hyopneumoniae antibody 
levels in bronchoalveolar lavage fluid of pigs from groups 1 through 4 at initial necropsy. 
Grou~ N VX/CH IgA IgG IgM 
1 4 P,M 0.017 ± 0.042 0.276 ± 0.192 0.820 ± 0.106 
2 4 M -0.022 ± 0.037 0.261±0.191 0.869 ± 0.097 
3 4 p 0.052 ± 0.112 0.066 ± 0.074 0.750 ± 0.038 
4 3 None -0.0003 ± 0.002 0.0003 ± 0.115 0.708 ± 0.020 
N = number of pigs 
P = PRRS vaccine, M = MH vaccine, CH = MH challenge 
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Table 4.6. Mean Optical Density (OD) values for Mycoplasma hyopneumoniae antibody 
levels in bronchoalveolar lavage fluid of pigs from groups 1 through 8 at final necropsy. 
Group N VX/CH lgA IgG lgM 
1 4 P,M 0.065 ± 0.029b,c 0.242 ± 0.161c 0.905 ± 0.116 
2 5 M 0.034 ± 0.044c 0.166 ± 0.244c,d,e 0.813 ± 0.171 
3 4 p 0.052 ± 0.057b,c -0.035 ± 0.055e 0.844 ± 0.170 
4 5 None 0.031 ± 0.068c 0.004 ± 0.080d,e 0.737 ± 0.056 
5 7 P,M.CH 0.378 ± o.102a 0.748 ± 0.128a 0.882 ± 0.246 
6 9 M,CH 0.389 ± 0.116a 0.572 ± 0.245b 0.884 ± 0.354 
7 9 CH 0.092 ± 0.041 b,c 0.078 ± 0.107c,d,e 0.715 ± 0.278 
8 7 P,CH 0.127 ± 0.039b 0.197 ± 0.185c,d 0.641±0.276 
N = number of pigs 
P = PRRS vaccine, M = MH vaccine, CH = MH challenge 
a,b,c,d,e Within each column, values with different superscripts are significantly different 
(p<.05). 
cells in all tissues. Results varied at the second necropsy with different groups showing 
higher levels in different tissues. 
Results of ELISA serology for MH in our study are shown as sample/positive 
control (SIP) values in Table 4.9. Mycoplasma serology was done on samples collected 
on days -8, 7, 14, 21, 28, 35, 50 and 62. Beginning on day 21 and continuing through the rest 
of the trial, the average mycoplasma titer of Group 5 was significantly higher than all other 
groups although this group and Group 1 had received identical treatment up through day 35. 
On day 36, Groups 5 through 8 received MH challenge. Groups 5 and 6, both MH vaccinated 
and challenged, had greatly elevated titers compared to other groups from day 28 on. 
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Table 4.7. ELISPOT assay: number of interferon-y producing cells per well in groups 1 
through 4 at first necropsy. 
Group VX/CH BLD1\1NS BLNMNS ILNMNS 
1 M, P 2.293 ± 1.877a,b 1.043 ± 0.835 2.168 ± 3.041 
2 M 0.277 ± 0.479b 0.557 ± 0.587 0.223 ± 0.387 
3 p 0.210 ± 0.317b 1.043 ± 0.977 0.208 ± 0.249 
4 None 0.110 ± 0.191b 0.167 ± 0.289 0.057 ± 0.098 
MV=:MH vaccine, PV=PRRSV vaccine, MC=MH challenge 
LNG1\1NS 
2.293 ± l.877a,b 
0.277 ± 0.479b 
0.210 ± 0.317b 
0.110 ± 0.191 b 
a,b Within each column, values with different superscripts are significantly different (p<.05). 
For Tables 4.7 and 4.8: BLDMNS=Mean count of response of blood mononuclear cells 
minus mean no-stimulation count. BLNMNS=Mean count of response of bronchial lymph 
node mononuclear cells minus mean no-stimulation count. ILNMNS=Mean count of 
response of inguinal lymph node mononuclear cells minus mean no-stimulation count. 
LNGMNS=Mean count of response of lung mononuclear cells minus mean no-stimulation 
count. 
Table 4.8. ELISPOT assay: number of interferon-y producing cells per well in groups 1 
through 8 at second necropsy. 
Group VX/CH BLD1\1NS BLNMNS ILNMNS LNG1\1NS 
1 M,P 0.043 ± 0.085 26.457 ± 41.880a 2.083± 3.530 1.710 ± 2.697 
2 M 3.568 ± 3.863a,b 0.832 ± l.257b 0.034 ± 0.076 0.200 ± 0.299 
3 p 0.083 ± 0.165b 5.000 ± 10.00b 0.250 ± 0.500 0.125 ± 0.250 
4 None 2.302 ± 2.970a,b 0.300 ± 0.671 b 1.166 ± 1.723 0.666 ± 1.086 
5 M, P, CH 7.691± 13.049a 0.214 ± 0.567b 0.476 ± 0.899 1.571±3.047 
6 M,CH 4.166 ± 6.217a,b 2.111±2.485b 0.833 ± 1.188 0.446 ± 0.602 
7 CH 0.556 ± 0.708b 0.870 ± 0.828b 0.814 ± 1.326 4.259 ± 6.027 
8 P, CH 1.786 ± 2.153a,b 1.239 ± 0.769b 0 1.453 ± 1.972 
MV=:MH vaccine, PV=PRRSV vaccine, MC=:MH challenge 
a,b Within each column, values with different superscripts are significantly different (p<.05). 
Table 4.9. Mean SIP (sample/positive control) ratios of Mycoplasma hyopneumoniae antibody levels in serum determined by ELISA. 
Group Day-8 Day7 Day 14 Day 21 Day28 Day 35 Day 50 Day62 
1-P,M 0.181 0.045 0.093 0.338 3.112 ± 1.2973 3.168 ± l.2523 'b 2.148 ± 0.808b,c 2.093 ± 0.858b,c,d 
2-M 0.13 0.072 0.120 0.164 2.759 ± 1.8263 2.708 ± l.884b 3.805 ± 2.4583 'b 2.751 ± l.846b,c 
3-P 0.125 0.246 0.322 0.316 0.214 ± 0.203b 0.178 ± 0.118c 0.161±0.130c 0.244 ± 0.236c,d 
4-None 0.142 0.084 0.047 0.078 0.059 ± 0.066b 0.071 ± 0.079c 0.151 ± 0.091 c 0.107 ± 0.101 d 
5-P, M, CH 0.147 0.161 0.223 1.303 4.440 ± 1.9523 5.136 ± 0.8933 5.668 ± 1.1723 6.176 ± 1.1583 ...... 0 
3.025 ± 1.061 b 3.300 ± l.055b 4.194 ± l.1533 'b °' 6-M, CH 0.085 0.140 0.180 0.236 3.133 ± 1.0913 
7-CH 0.086 0.106 0.058 0.095 0.081±0.094b 0.099 ± 0.076c 0.105 ± 0.074c 0.176 ± 0.145d 
8-P, CH 0.098 0.071 0.057 0.087 0.079 ± 0.091 b 0.110 ± 0.093c 0.178 ± 0.135c 0.230 ± 0.202c,d 
3 ,b,c,<l Within each column, values with different superscripts are significantly different (p<.05). 
P= PRRS vaccination, M= mycoplasma vaccination, CH= mycoplasma challenge 
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Discussion 
Growth performance of pigs did not vary significantly between the individual groups. 
In our MH challenge system, pigs in well-ventilated isolation rooms with ad libitum feeding 
normally perform well with minimal effects due to mycoplasmal challenge. Overall from day 
0 to day 62 though, when comparing total gain, non-MH vaccinated pigs demonstrated 
approximately a 6% reduction in growth compared to mycoplasma vaccinated pigs (1.45 
lbs/day for non-vaccinates vs. 1.53 lbs/day for vaccinates, not considering the effects of 
PRRS vaccination or MH challenge). Through 62 days we found approximately a 5% 
reduction in growth when comparing challenged pigs to non-challenged pigs. Although 
differences were not significant one could expect that the growth depression said to be 
associated with mycoplasma challenge, especially in non-vaccinated pigs, would begin 
approximately one to two weeks post-challenge, when clinical signs are first appearing. 
Pneumonic lesions attributable to MH were significantly elevated in challenged pigs 
not immunized against MR. PRRS vaccination status did not affect MH vaccine efficacy. 
MR vaccination reduced the extent of lesions, as previously reported. 137 Vaccination did not 
eliminate mycoplasmal colonization. 
The initial PRRS serology on day -8 revealed that all pigs were seronegative. All 
vaccinated pigs were positive by 14 days and there were no significant differences among the 
vaccinated groups at this time. At 62 days, the PRRS vaccinated groups also receiving MR 
vaccine had titers significantly lower than the groups receiving only PRRS vaccine. 
Apparently the MH bacterin may have interfered with responses to the PRRS vaccine even 
though the first dose of mycoplasma bacterin was given 8 days after the PRRSV vaccination. 
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Challenge with :M1I had no effect on PRRS titers. 
Weng and Chu175 found that tracheobronchial washings from :M1I vaccinated pigs had 
IgG fractions detectable at 6 weeks. In :MII-challenged pigs, IgA was found in 
tracheobronchial secretions at 2 weeks post-inoculation. At 6 and 12 weeks, mainly IgA with 
some IgG was found, while from 20 weeks until the end of their study, only IgA was 
detectable. Also in their study, bronchial lymph node lymphocytes of vaccinated pigs were 
preferentially stimulated at four and seven days post-challenge with down-regulation by day 
11. An increase in cellular responses in systemic lymphoid organs was seen on day 11 post-
challenge. The conclusion was that vaccination appeared to prime helper T cells in localized 
lymphoid tissues which subsequently activate local effector cells for control of infection. 
Groups 1 through 4 in our study were divided into the first and second necropsies for 
evaluation of BALF antibodies. The first necropsy was done to establish baseline data and 
assess potential problem areas in the assay prior to evaluating the challenged pigs. Local 
antibody production is an essential protective mechanism in the lung, but in our study it 
appears that initial priming via vaccination followed by challenge was necessary for detecting 
statistically significant differences. Groups 5 and 6 that received both :M1I vaccination and 
challenge developed the highest IgA and IgG antibody levels in the BALF. It does not appear 
that evaluation of local immunity (either IgA or IgG) is possible prior to challenge. Group 5 
pigs, that also received PRRS vaccine, had significantly higher levels of IgG than group 6 
pigs, that did not receive the PRRS vaccine. Others have reported enhanced serum antibody 
production to another vaccine in pigs also receiving PRRS vaccine. 164 There were no distinct 
differences in IgM responses; they exhibited a high background similar to the no~-specific 
109 
responses found in our first study. Some of the samples were contaminated with blood and 
thus with immunoglobulins from the serum. However, the contamination did not correlate 
with the immunoglobulin levels and values were not adjusted. 
Suter154 previously evaluated antibody levels in tracheobronchial secretions and found 
elevated levels 2 weeks after infection. It would have been interesting to ascertain whether 
any differences could be noted earlier after challenge in our study; however that would have 
necessitated either more necropsy dates, and thus less statistical power overall, or 
bronchoalveolar lavage under anesthesia. Some researchers have noted that bronchoalveolar 
lavage in live pigs may contribute to pneumonia development which would possibly skew 
results. 
Interferon-gamma production by mononuclear cells was selected for evaluation due to 
findings that mycoplasma vaccination, specifically Respisure™, has been shown to induce its 
secretion.164 IFN-y enhances activity of NK cells and macrophages.93 It also can increase 
MHC expression which is important in antigen presentation and might aid B cell-T cell 
interactions. 93 
At the first necropsy, pigs in Group 1 that received both vaccines had higher levels of 
IFN-y secreting cells in the blood and inguinal lymph node than Groups 2, 3 and 4. Levels of 
secreting cells in the bronchial lymph node are comparable between Group 1 pigs receiving 
both vaccines and pigs in Group 3 that received only the PRRS vaccine. 
At the second necropsy in the bronchial lymph node, Group 1 had significantly higher 
numbers of cells secreting IFN-y. In the blood, pigs receiving both MH and PRRS vaccines 
(Groups 1 and 5) had high numbers of cells secreting IFN-y. 
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There were some inconsistencies in the ELISPOT assay that may have affected the 
results . ConA stimulation, intended as a positive control, was not equal for all groups in 
analysis of bronchial lymph node and lung reactivity. The negative control (Nostim) counts 
varied widely in the bronchial lymph node assay for IFN-y production. 
In the ELISPOT analysis for IFN-y production at the second necropsy, significant 
differences were found when comparing Group 5 pigs given both vaccines and then 
challenged with MH to Group 1 pigs that were immunized with both vaccines but were not 
challenged. Group 5 pigs demonstrated much greater levels of responsive cells in the blood 
than the Group 1 pigs (mean values of 7.691 versus 0.043) implying that challenge stimulated 
the cells or increased the rapidity with which they could respond. In the bronchial lymph 
node, Group 1 pigs at the second necropsy had very high counts compared to Group 1 pigs at 
the first necropsy (mean values of 30~085 versus 1.043, P < 0.001). One also would have to 
consider that the age of the animal may have some effect or perhaps the period of time 
following vaccination influenced the number of responding cells. 
In the bronchial lymph node at the second necropsy, Group 1 pigs had higher levels of 
responding cells compared to Group 5 (mean values of 30.085 versus 0.214, P < 0.001). In 
the blood, comparatively high numbers of mononuclear cells of pigs given both vaccines and 
then challenged respond to MH antigen stimulation with the production of IFN-y. In the 
bronchial lymph node, though, challenge results in very low levels of response, compared to 
negative controls. Surprisingly, lung tissue mononuclear cells did not react to stimulation to 
any great degree. If, as is thought, IFN- y is necessary to drive the cell-mediated immune 
response, we would expect local lung lymphocytes to be producing this cytokine. Perhaps 
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the length of time from stimulation to necropsy resulted in a return to "normal" production. 
Mycoplasma serology results show that at day 28, as expected, all mycoplasma 
vaccinated pigs had titers significantly higher than those from non-vaccinated pigs. Whether 
or not pigs were also given PRRSV vaccine did not appear to impact the pigs' antibody 
responses to mycoplasma vaccination. In fact, on days 28 and 35, the results suggest that 
administration of the PRRSV vaccine enhanced antibody responses to the mycoplasma 
vaccine. Mycoplasma challenge did not occur until day 36 so there could be no added benefit 
from that contributing to the antibody responses on days 28 and 35. Through days 50 and 63, 
MH vaccinated pigs maintained their high antibody levels compared to non-vaccinated pigs. 
Challenged pigs demonstrated the highest levels with no detrimental effects from PRRSV 
vaccination noted. Thus it would appear that administration of a modified live PRRSV 
vaccine does not adversely affect the pigs' humoral immune response to this killed MH 
bacterin. 
Conclusion 
Respiratory disease due to infection with Mycoplasma hyopneumoniae complicated 
by secondary bacterial and/or viral pathogens is a significant economic burden to swine 
producers throughout the world. PRRSV is one pathogen that has recently come into focus 
as having a large impact on respiratory disease in the grow/finish pig. Vaccination against 
MH and/or PRRSV has become common in many herds. Most PRRS vaccines utilized by 
producers are ML V vaccines and must infect the animal to generate immunity. In our study 
we attempted to identify specific interactions between a modified live virus PRRS vaccine 
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and a MI-I bacterin that could result in interference with the development of protective 
immunity. Pigs challenged with MI-I after receiving both PRRS and MI-I vaccines, however, 
were not found to be any more susceptible to lesion development than pigs that received only 
the MI-I vaccine prior to challenge. In fact, the PRRSV vaccine seemed to augment antibody 
development to the MI-I bacterin. Although enhanced antibody development does not 
necessarily imply more or better protection, it does indicate that the humeral arm of the 
immune system in the pig is better stimulated by the MI-I bacterin when the vaccine virus is 
present. Conversely, administration of the MI-I bacterin appeared to interfere with 
development of antibodies to the PRRSV vaccine. The pigs were not challenged with 
PRRSV and thus evaluation of protective immunity was not possible so whether this 
reduction in antibody response was detrimental cannot be determined. It is not known 
whether administration of the ML V PRRS vaccine at different times relative to the MI-I 
vaccinations would alter the results we obtained. 
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CHAPTER 5. CONCLUSION 
Respiratory disease in the pig continues to be a major economic problem which swine 
producers and veterinarians deal with on a daily basis. With the advent of new viral 
pathogens such as porcine reproductive and respiratory syndrome virus (PRRSV), MH has re-
emerged as a major co-contributor to the porcine respiratory disease complex. Control 
methods used in the past have involved medications, vaccinations and management. A 
combination of these methods have usually been necessary for optimum pig performance. 
Vaccines have been variable in effectiveness in protecting against clinical disease in 
an individual swine herd. Since each swine herd maintains a separate ecosystem, blanket 
recommendations cannot be depended on to yield the same results. We have attempted to 
explore complex interactions by only varying one or two independent aspects in our research 
on porcine respiratory disease related to MH infection. We know that both the cellular and 
humoral (local and systemic) immune systems are important in generating protection against 
clinical disease due to MH. We believe that systemic antibody production is not correlated 
with protection. Systemic antibody to MH develops rather slowly after infection and/or 
vaccination and antibody titers are generally much higher in vaccinated pigs. Relatively high 
levels of MR-specific IgA and IgG can be found in the lung after pigs receive infectious 
challenge even while the immune responses in the lung and bronchial lymph node, in general, 
are greatly enhanced due to the influx of a number of antibody-producing B lymphocytes. 
The response of IgM-secreting cells is non-specific. 
We have demonstrated that the administration of a modified live PRRSV vaccine 
does not adversely affect protective immunity generated by a MH bacterin, at least in the 
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context in which they were used in our study. Evaluation of the antibody production 
generated by the two vaccines when both are given to a pig implies some definite direct cell-
to-cell and/or cytokine/cell interactions. More work is needed on the mechanisms of 
pathogenesis of MH and the protective role of local versus humoral immunity generated by 






































APPENDIX A: LIST OF ABBREVIATIONS 
Actinobacillus pleuropneumoniae 
bronchoalveolar lavage fluid 
bovine serum albumin 
chemiluminescence 
enzyme-linked immunosorbent assay 
fluorescent antibody 
fetal calf serum 






li popol ysaccharide 
Mycoplasma hyopneumoniae 
modified live virus (vaccine) 
natural killer (cell) 
nanometer 
porcine alveolar macrophages 
peripheral blood mononuclear cells 
phosphate-buffered saline solution 
phosphate-buffered saline/tween solution 




porcine respiratory disease complex 
porcine reproductive and respiratory syndrome virus 
severe combined immunodeficiency 
sodium dodecyl sulfate 
segregated early weaning 
swine influenza virus 
specific pathogen free 
T cell receptor 
tumor necrosis factor 
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APPENDIX B: REAGENTS 
lOX ELISA wash, 8.5% NaCl solution with 0.5% Tween 20 
43.38 g NaCl 
2.5 ml Tween 20 
q.s. 500 ml with deionized water 
lX ELISA wash 
100 ml lOX ELISA wash 
900 ml deionized water 
5X TSE, ph 7.4 
15.125 g of 0.25 M Tris HCl 
21.91 g of 0.75 M NaCl 
0.93 g of 5 mM EDTA 
450 ml deionized water 
Adjust to pH of 7.4 with concentrated HCl 
q.s. 500 ml with deionized water 
lX TBSE buffer 
for 3 microtiter plates: 30 ml 5X TSE 
120 ml deionized water 
0.15 g BSA 
7 5 µl Tween 20 
10% SDS 
10 g sodium dodecyl sulfate 
100 ml deionized water 
1% SDS 
100 ml 10% SDS 
900 ml deionized water 
Peroxidase conjugated rabbit anti-swine IgG (Cappel) 
PBST 
For 2 microtiter plates: 23 µl conjugate 
250 µl 0.05% Tween 
500 ml PBS 
23 ml lX TBSE buffer 
FACs buffer 
1 % bovine serum albumin 
0.1 % sodium azide 
PBS 
Carbonate/bicarbonate buff er 
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Solution A: 2.12 g sodium carbonate in 100 ml deionized water 
Solution B: 3.36 g sodium bicarbonate in 200 ml deionized water 
For 2X solution: Mix 65 ml of solution A with 185 ml of solution B 
Adjust pH to 9.5-9.6 if necessary 
Use as lX solution: Dilute 1: 1 with deionized water 
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